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Children with sickle cell disease (SCD) are at an increased risk of stroke. 
Transcranial Doppler (TCD) screening assesses the risk of stroke in children with SCD 
by measuring blood velocity in cerebral vessels. High velocities are strongly associated 
with stroke risk and indicate the need to begin chronic blood transfusions as a stroke 
prevention strategy. Although chronic blood transfusions have been known to reduce 
stroke risk by up to 92% since the nineties, rates of TCD screening remain low and few 
factors have been identified that are associated with receipt of TCD screening. This 
dissertation investigated factors that may influence receipt of TCD screening among 
children with SCD on multiple levels by 1) assessing TCD screening rates and 
frequency and predictors of missed opportunities among children with SCD in Michigan 
Medicaid, 2) exploring the role of neighborhood factors in receipt of TCD screening 
among children with SCD in Michigan Medicaid residing in Wayne County, and 3) 
investigating physician awareness, attitudes and knowledge of TCD screening 
guidelines, along with physician perceived barriers to screening. 
Assessment of TCD screening rates and missed opportunities in children with 
SCD enrolled in Michigan Medicaid showed that TCD screening rates were low, 
particularly among adolescents. Low TCD rates coupled with high healthcare utilization 
resulted in frequent missed opportunities for TCD screening. Increasing age was 
associated with an increased likelihood for a missed opportunity, while more than 4 
outpatient visits and previous receipt of TCD screening decreased the odds for a 
missed opportunity. No association was found between receipt of TCD screening and 
xi 
  
socio-demographic characteristics of the child’s neighborhood, nor was any spatial 
pattern of screening rates discovered across neighborhoods. Although physicians 
believed that children with SCD should receive TCD, significant differences existed in 
awareness, attitudes and knowledge of TCD screening guidelines across specialties, 
and knowledge of specific TCD recommendations was low for all physicians. The 
culmination of this work suggests that future studies and interventions are necessary to 
continue to identify and intervene on factors associated with TCD screening among 






Pediatric stroke is a leading cause of childhood death. Among survivors, pediatric 
stroke is associated with significant morbidity such as stroke recurrence and cognitive 
and behavioral deficits. In the US, annual pediatric stroke incidence is ~2.4 in 100,000; 
however, risk in children with sickle cell disease (SCD) is much higher. Without 
intervention, ~10% of children with SCD will have a stroke by age 20. These strokes are 
largely preventable. Transcranial Doppler (TCD) screening is used to detect high blood 
flow velocities in cerebral vessels of children. High velocities indicate an increased 
stroke risk and the need to begin stroke prevention in the form of blood transfusions 
with the goal to reduce hemoglobin S below 30%. Once transfusions are initiated, stroke 
incidence is reduced by up to 90%. Given the importance of stroke prevention in this 
population, the National Heart Lung and Blood Institute (NHLBI) recommends children 
with SCD receive one TCD screening per year from ages 2 to 16 years. However, rates 
of screening remain low, even in comprehensive sickle cell centers. Little is known 
regarding the factors that influence TCD screening among children with SCD to inform 
interventions to improve screening in this high-risk population. 
The objective of this dissertation was to identify policy and practice intervention 
targets to improve access to and use of TCD screening with the intent to reduce 
pediatric stroke among children with SCD. The research used Michigan Medicaid data 
from 2007 to 2011 to identify rates of TCD screening in Michigan, along with the 
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frequency and individual-level correlates of missed opportunities for TCD screening. 
The role of neighborhoods in the receipt of TCD screening was also investigated. In 
addition, provider knowledge regarding current recommendations for TCD screening 
and provider perceived barriers to TCD screening among children with SCD were 
explored. 
 
1.2 Specific Aims and Hypotheses 
The specific aims and hypotheses for this dissertation were as follows: 
Aim 1a: Determine the frequencies of TCD screening and missed opportunities for TCD 
screening among children with SCD continuously enrolled in Michigan Medicaid for at 
least one year from 2007 to 2011. 
Hypothesis 1a: Rates of TCD screening will be low and the frequency of missed 
opportunities for TCD screening will be high, suggesting significant potential to increase 
TCD screening rates through reduction of missed opportunities. 
Aim 1b. Identify individual-level correlates (SCD-related healthcare utilization, SCD 
comorbidities, and previous receipt of TCD screening, demographics and sickle cell 
type) of missed opportunities among children with SCD continuously enrolled in 
Michigan Medicaid for at least two years from 2007 to 2011. 
Hypothesis 1b: SCD-related emergency department utilization, hematologist visits, SCD 
comorbidities, sickle cell type (Hemoglobin SS), SCD severity, decreasing age and 
female sex will be associated with fewer missed opportunities. 
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Aim 2a: Investigate the spatial pattern of TCD screening rates across neighborhoods of 
children with SCD continuously enrolled for at least one year in Michigan Medicaid from 
2007 to 2011. 
Hypothesis 2a. A spatial pattern of TCD screening rates will be present across 
neighborhoods and pockets of neighborhoods with low TCD screening rates will be 
identified. 
Aim 2b. Identify neighborhood-level factors related to the receipt of TCD screening 
among children with SCD continuously enrolled in Michigan Medicaid for at least one 
year from 2007 to 2011. 
Hypothesis 2b. Increasing neighborhood disadvantage, as measured by percent less 
than high school education, percent African American residents, percent unemployment 
and decreasing median household income, will be associated with lack of receipt of 
TCD screening among children with SCD. 
Aim 3: Explore factors that may be related to adherence to TCD screening guidelines 
among physicians (awareness, attitudes and knowledge of guidelines) and assess 
physician-perceived barriers to TCD screening among pediatric primary care physicians 
of children with SCD in Michigan and pediatric hematologists and neurologists across 
the United States. 
Hypothesis 3a: Awareness, attitudes and knowledge of TCD screening guidelines will 
differ by provider specialty. 




A more complete understanding of the determinants of TCD screening among 
children with SCD is integral in order to develop targeted interventions to increase TCD 
screening rates. The results of this research could inform interventions at multiple levels 




Public Health Importance of Pediatric Stroke 
Incidence rates for pediatric stroke are estimated to range from 1.3-13.0 per 
100,000.1,2 Pediatric stroke is associated with significant mortality, morbidity and cost. 
Mortality rates from pediatric stroke are 0.23 per 100,000,3 and pediatric stroke is one of 
the top ten causes of childhood death in the US.4 In one study of children hospitalized 
with stroke, 74% showed significant neurological deficits at discharge.5 Another study 
focusing on the one year post-stroke period showed 54% of children with severe 
neurological impairment.6 Health related quality of life is significantly lower among 
children who have had a stroke compared to their healthier counterparts.6 Rates of 
recurrence are high, with 25% of children having a recurrent stroke within two years of 
initial stroke.7 The median five year direct costs of inpatient and outpatient care of a 
pediatric stroke patient total $135,161, with the initial hospital admission contributing 
$81,869.8 The lifelong cost of pediatric stroke is likely far greater due to the large 
burden pediatric stroke places on both families and society.9 
Risk factors for pediatric stroke differ from those for adult stroke. Identified risk 
factors for arterial ischemic stroke include sickle cell disease (SCD), varicella infection, 
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arteriopathy and cardiac disease. These risk factors vary by both child age and 
geographic location.10 Vascular abnormalities are commonly associated with pediatric 
hemorrhagic stroke.11 
Disparities in pediatric stroke exist as African American children are at a twofold 
greater risk of stroke compared to white children; however, the disparities between 
black and white children have decreased over the past decade for ischemic stroke but 
remained stable for hemorrhagic stroke.12,13 This disparity may be largely due to SCD 
which occurs primarily in African Americans. The reduction in this disparity over time 
may be partially attributable to the impact of stroke prevention efforts among children 
with SCD. Males compared with females are at an increased risk of both incident stroke 
and death due to pediatric stroke across all ages and stroke subtypes.12,14 
Sickle Cell Disease 
Sickle cell anemia is a genetic condition due to a point mutation in a hemoglobin 
molecule. Sickle cell hemoglobin (HbS) is a recessive trait that can be inherited as 
sickle cell trait (one HbS gene) or SCD.15 There are three main subtypes of SCD: HbSS 
(two sickle cell genes), HbSC (one sickle cell gene and one gene for abnormal 
hemoglobin called C) and HbS β-thalassemia (one sickle cell gene and one β-
thalassemia gene, a type of anemia).16 SCD currently affects approximately 70,000-
100,000 Americans. SCD disproportionately impacts minorities; 1 out of 500 African 
American births and 1 out of 36,000 Hispanic American births are diagnosed with 
SCD.16,17 Sickle cell trait is generally asymptomatic but a genetically important variant 
which affects 1 in 12 African American births. 
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In individuals with SCD, hemoglobin has a sickle shape as opposed to the disc 
shape in individuals with normal hemoglobin. This sickle shape has two major health 
consequences: anemia and blood vessel occlusion. The sickle shape of the cells 
promotes adherence to the endothelial cells which leads to endothelial activation. 
Endothelial activation initiates the release of several activator substances, along with 
impairing the release of nitrous oxide (a vasodilator). These factors cause the blood 
vessel occlusion in SCD.15 The severity of symptoms in SCD is controlled by the 
amount of sickling of the HbS, along with other factors such as temperature, stress, 
infection, dehydration, or hypoxia. Blood vessel occlusion can result in severe pain 
crises in individuals with SCD, which can happen suddenly and in many areas of the 
body. Acute chest syndrome (atypical pneumonia), growth retardation, osteomyelitis, 
swelling, neurological complications and splenic injury are common morbidities of 
SCD.15 Additionally, children with SCD have a significant increased risk for infection as 
they are 100 times more likely to develop pneumococcal infection than children without 
SCD.18 The high rate of health complications among children with SCD also leads to 
increased healthcare utilization and expenses. Children with SCD are 7-30 times more 
likely to be hospitalized, 2-6 times more likely to visit the emergency department, and 
have over 8 times the healthcare expenditures than their healthier counterparts.19-21  
To facilitate early identification of children with SCD, all states perform Newborn 
Screening (NBS) upon birth.22 The American Academy of Pediatrics (AAP) has released 
recommendations regarding coordination between NBS and primary care physicians 
(PCPs) in the reporting of NBS results, and states are also responsible for program-
specific information regarding follow-up.23 Despite identification of SCD at birth, delayed 
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or inadequate preventive services may lead to serious complications and/or premature 
death in children with SCD.18,24,25 
Pediatric Stroke and Sickle Cell Disease 
The sickle shape of the blood cells among those with SCD prevents smooth 
motion through blood vessels. These cells can easily form clumps that may then get 
stuck in the blood vessels. This clumping of blood vessels may explain small vessel 
infarcts. There is no known association between sickle cell trait and stroke;26 however, 
children with SCD have over three hundred times the stroke risk than children without 
SCD or heart disease.27 Without intervention, approximately 11% of children with SCD 
will have a stroke by age 2027,28 and 24% by age 45.28,29 The mechanism for stroke in 
patients with SCD is poorly understood. 
Predicting Stroke Risk Among Children with SCD 
Transcranial Doppler Ultrasonography (TCD) has been shown to have 90% 
sensitivity and 100% specificity in detecting significant intracranial lesions by detecting 
high blood flow velocities in arteries, specifically the distal internal carotid artery (ICA) or 
proximal middle cerebral artery (MCA).30,31 Children over the age of two with a time-
average mean maximum blood flow velocity of 200cm/sec or greater as measured by 
TCD have been shown to have 27 times the risk of stroke than children with velocities 
less than 200cm/sec. This corresponds to a 40% risk of stroke among those with high 
velocities within 3 years.30 TCD screening is a reasonable method to assess stroke risk 
among children with SCD, as it is safe, non-invasive and low cost.32 Although other 
predictors of stroke have been examined such as hematocrit levels and white blood cell 
count, TCD has been shown to be the only independent predictor of stroke.31 
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Stroke Prevention Among Children with SCD 
The Stroke Prevention in Sickle Cell Anemia (STOP) trial aimed to test the 
hypothesis that blood transfusions would reduce the risk of stroke among children with 
SCD. Children with SCD with no history of stroke, no transfusion contraindications, and 
at no additional risk of stroke due to external factors received TCD screening. Results 
from the TCD screening were characterized as normal (blood velocities in the MCA or 
ICA less than 170cm/sec), conditional (velocities 170-200cm/sec) or abnormal 
(velocities 200cm/sec or greater). Children with at least two abnormal TCD results were 
randomized to either receive standard care for children with SCD (vaccinations, folic 
acid supplementations, etc.) or transfusions every 3-4 weeks with the goal to reduce 
hemoglobin S concentration to below 30% of total hemoglobin. The primary endpoint of 
the trial was stroke as determined by a blinded physician panel. A total of 130 children 
were enrolled and 63 were randomized to receive transfusions. Eleven children in 
standard care and one child on transfusions had a stroke, resulting in a 92% stroke 
relative reduction among children receiving transfusions as opposed to standard care.24 
The trial was stopped early due to the large benefit of transfusions. Given the results of 
the STOP trial, the NHLBI released a clinical alert in 1997 recommending TCD 
screening for children with SCD between the ages of 2 to 16 years.33 
The STOP2 trial randomized children who had received exchange transfusions 
for thirty months or longer to either continue or discontinue exchange transfusions. 
Discontinuation led to a high rate of abnormal blood flow velocities on TCD screening 
and an increased risk of stroke.34 Once again, the trial was stopped early due to the 
benefit of continued exchange transfusions. 
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Another potential method of stroke prevention that has received recent attention 
is hydroxyurea therapy. Hydroxyurea, a medication used for pain treatment in adults 
with SCD, has been shown to reduce blood velocities as detected by TCD screening in 
children with SCD;35 however, a recent study investigating if hydroxyurea was as 
effective at preventing recurring strokes in children with SCD was halted as the 
hydroxyurea approach seemed no better than the standard treatment of exchange 
transfusions.36 
Recommendations for TCD Screening 
Given the importance of TCD screening to indicate the need to begin stroke 
prevention efforts, numerous organizations have released guidelines regarding TCD 
screening among children with SCD. These guidelines differ among the organizations in 
integral areas. NHLBI guidelines, “Management of Sickle Cell Disease” (2002), 
recommend TCD screening to start in children with SCD (HbSS) at age two and 
continue until age sixteen. If TCD screening is normal (blood velocity <200 cm/second), 
children are recommended to receive one screening annually. If TCD screening results 
are >200 cm/second, the results are considered abnormal. Abnormal results indicate 
the need for additional screening.25 Recommendations from the American Heart 
Association (AHA) are similar but less specific, indicating that children with SCD in 
general should be screened with TCD beginning at two years of age, and screened 
more frequently if velocities are near the 200 cm/sec cutoff.37 The AHA also suggests 
using peak systolic velocities as a measurement as opposed to time-averaged means of 
maximum velocity used in the STOP trial. The American Academy of Neurology (AAN) 
recommends beginning TCD screening at two years38 and the AAP recommends 
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physicians discuss TCD screening if available from ages one to thirteen; however, 
provides neither specific indications for the timeliness nor appropriateness of TCD 
screening.39  
The AAP recommendation has received backlash from physicians, prompting a 
letter to the editor questioning the weak recommendations in the face of compelling 
evidence.40 The AAP reply to the letter defends the organization’s position, stating that 
the long-term risks and benefits are unclear for TCD screening due to transfusion 
related morbidity and lack of standardization of screening methods. The significant 
ambiguities and disparities that exist between multiple national organizations’ guidelines 
(Table 1.1) may lead to differences among physicians in recommendations regarding 
TCD screening. 
Rates of TCD Screening Among Children with SCD 
Although rates of TCD screening have increased six-fold since the STOP trial 
among children with SCD, they remain significantly lower than the NHLBI guidelines of 
one TCD screening per year in numerous settings.41-43 The TCD screening rate in a 
large healthcare plan was 11.4 per 100 person-years in 2004.41 At a large, 
comprehensive sickle cell center in Philadelphia, 84% of 530 children with SCD at the 
center received screening over an eight year period, averaging only 3.3 screenings per 
child.44 At the Texas Children’s Sickle Cell Center, the average yearly screening rate for 
eligible patients was 45%.42 
A recent study utilized administrative claims from Tennessee Medicaid and chart 
review in two sickle cell centers to show that 68.6% of children with SCD received at 
least 1 TCD screening within a 12 year period, and yearly cumulative incidence rates of 
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annual TCD screening increased from 2.5% to 68.3% from 1997-2008.45 To date, TCD 
screening rates have largely been explored at comprehensive SCD care centers, which 
may not be representative of screening rates in the broader population of SCD patients. 
Individual-Level Predictors of TCD Screening Among Children with SCD 
Predictors of TCD screening are not well understood. Sickle cell type HbSS, 
distance of less than 30 miles to a vascular laboratory, and presence of hypertension 
have been shown to be predictors of TCD screening in a California HMO. 41 At two 
sickle cell clinics in Tennessee, calendar year, maternal education, and increased 
number of sickle cell related outpatient visits were associated with increased screening 
rate.45 Aside from these few studies, there is little published data on the factors 
associated with TCD screening. Additionally, these factors have been explored in 
specific SCD populations; therefore, these associations may not be generalizable to the 
population of children with SCD as a whole. 
Barriers to TCD Screening Among Children with SCD 
Both caregivers and providers play an integral role in stroke prevention among 
children with SCD. A survey of caregivers of children with SCD indicated lack of 
knowledge as the most important barrier to annual TCD screening, with over one-fifth of 
caregivers unaware of TCD screening.46 A lack of self-efficacy such as believing there is 
nothing one can do to prevent stroke was another barrier identified among caregiver 
respondents. Importantly, the vast majority of caregivers expected their healthcare team 




Little is known regarding provider knowledge and perspectives regarding TCD 
screening among children with SCD. A survey of hematologists in the United States 
pointed to poor patient adherence, distance to a vascular laboratory, and lack of 
appropriate staff to perform and interpret TCD screening results as perceived obstacles 
to TCD screening.47 The generalizability of this study is limited by both a low response 
rate and inclusion of hematologists only. The AAP recommends each child with SCD 
have a “medical home,” which may be either a sickle cell center or a primary care 
physician giving day-to-day care to the patient with referrals to specialists for the 
treatment of severe complications.39 Therefore, it is important to understand the 
attitudes and practices of pediatricians treating children with SCD. A national random 
sample of pediatricians showed only 35% of the pediatricians would be comfortable 
being the primary care physician for a child with SCD.48 One study showed that a 
majority of pediatricians are familiar with guidelines regarding antibiotic prophylaxis 
among children with SCD;49 however, TCD guidelines are newer and more controversial 
than guidelines regarding antibiotic prophylaxis. No study to date has investigated 
pediatricians’ knowledge regarding TCD screening or their perceived barriers to TCD 
screening among children with SCD. 
Missed Opportunities and Strategies to Improve TCD Screening 
Healthcare utilization is significantly higher in children with SCD than in children 
without SCD, although the type of healthcare can vary substantially between ED visits, 
hospitalizations, outpatient visits, home healthcare visits and participation in 
comprehensive SCD healthcare.50 With high healthcare utilization among children with 
SCD but low rates of TCD screening, “missed opportunities” for TCD screening may be 
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numerous. Other areas have successfully utilized the missed opportunity framework to 
identify opportunities to increase prevention efforts. For example, the immunization 
literature has a long history of identifying missed opportunities and factors related to 
missed opportunities.51,52 Interventions aimed at reducing missed opportunities for 
vaccination have also been successful.53,54 In contrast, no study has investigated 
predictors of missed opportunities for TCD screening among children with SCD, and 
there are few published intervention studies focused on improving TCD screening in 
children with SCD. In one example, a comprehensive TCD screening program was 
implemented at St. Jude Children’s Research Hospital which targeted all sickle cell 
children treated at the hospital. By the third year of the program, 99% of the children 
identified as at-risk had received at least one TCD screening, showing the effectiveness 
of an intervention aimed at increasing TCD screening rates.55 Utilizing the missed 
opportunity framework for TCD screening is a novel approach to identify opportunities 
for more targeted interventions which have the potential to increase screening rates 
among children with SCD. 
 
1.4 Public Health Significance 
Pediatric stroke is one of the top ten causes of childhood death in the US and is 
associated with significant mortality, morbidity, and costs. Children with SCD suffer a 
disproportionate burden of pediatric stroke. As SCD contributes to the race differences 
in childhood stroke risk, preventing stroke among this high-risk population may be the 
only avenue to minimize these disparities. These strokes can be largely prevented 
through initiation of chronic exchange transfusion therapy after detection of high blood 
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velocities through TCD screening; however, TCD screening rates are suboptimal among 
children with SCD. As children with SCD have frequent healthcare encounters but TCD 
screening remains low, missed opportunities for TCD screening exist. Michigan 
Medicaid administrative data for a five year time period was utilized to explore the 
individual- level and area-level predictors of missed opportunities for TCD screening. 
Additionally, this research explored provider awareness, attitudes and knowledge 
regarding current recommendations for TCD screening in children with SCD, along with 
provider perceived barriers of TCD screening. The results of this research could inform 
the development of targeted interventions at multiple levels (individual, area, provider) 




Table 1.1 Guideline Comparison for Transcranial Doppler Screening Among Children 











National Heart Lung 
and Blood Institute 
(2002)25 
2 - 16 years SC-SS Repeat 3-12 Months < 200 cm/second 
American Academy of 
Pediatrics (2002)39 1 - 13 years  Discuss screening if available  
American Academy of 
Neurology (2004)38 2 years - ?  Optimal Frequency unknown 
Mentions STOP 
cutoff of 200cm/sec 
American Heart 





Frequency needed to detect 
most cases at risk has not 
been determined; may be 
performed annually for cases 
in which the risk of 











Aim 1: Missed Opportunities for Transcranial Doppler Screening 
Among Children with Sickle Cell Disease
 
2.1 Introduction 
Pediatric stroke is one of the top ten causes of childhood mortality and is also 
associated with significant morbidity and cost.56 Children with SCD are at an increased 
risk for stroke.3,4,8 Without intervention, 11% of children with SCD would have been 
expected to have a stroke by age 20; however, the majority of these strokes are now 
considered preventable.27-29 TCD detects blood velocities in cerebral vessels; high 
velocities are indicative of a high stroke risk and indicate the need to begin preventive 
efforts in the form of blood transfusions to maintain low hemoglobin concentrations.30 
The Stroke Prevention in Sickle Cell Anemia (STOP) trial in 1998 found that 
stroke risk was reduced by 92% in children receiving chronic blood transfusions after 
detection of high blood velocities by TCD screening as compared to those not receiving 
transfusions.24 Given the impact on stroke risk reduction seen in the STOP trial, the 
NHLBI guidelines recommend that TCD screening be initiated for children with SCD at 2 
years old, and if TCD results show normal blood velocities, subsequently receive one 
screening annually until 16 years old.25 
Healthcare utilization is often high in children with SCD, as this population has 7-
30 times the hospitalization rates, 2-6 times the emergency department visits, and over 
8 times the healthcare expenditures compared to their counterparts without SCD.19,21,57 
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This suggests access to health services may not be a substantial barrier to TCD 
screening.58 Even with frequent contact with the healthcare system, TCD screening 
rates are still substantially lower than the goal of each child with SCD having one TCD 
screening per year, as indicated by the NHLBI guidelines.41,42 One contributing factor 
may be missed opportunities for TCD screening, where a child with SCD who is eligible 
for screening has a health service encounter, yet does not have a TCD screen 
performed. We hypothesized that missed opportunities for TCD screening may be 
numerous in children with SCD, given frequent healthcare interactions and low TCD 
screening rates. The objective of this study was to assess TCD screening rates and the 
frequency and predictors of missed opportunities for TCD screening in children with 
SCD. We also estimated the maximum TCD screening rates potentially achievable 




Administrative data from Michigan Medicaid for the years 2007 to 2011 were 
queried from the Michigan Department of Community Health (MDCH) data warehouse, 
including enrollment history and claims for inpatient, emergency department, outpatient, 
and pharmacy services. Michigan Medicaid enrollees were linked to newborn screening 
results through birth certificates to identify children with SCD born from 1987 to 2008 




Inclusion Criteria. Children with SCD were identified as those having hemoglobin 
(HgB) SS or HgB S/β0 Thalessemia disease; the former subtype is specifically cited in 
NHLBI recommendations regarding TCD screening while both variants were included in 
the STOP trial.24,25 Children 2 to 16 years old were eligible to be in the study population 
if they were continuously enrolled in Michigan Medicaid for at least one year from 
January 1st and December 31st from 2007 to 2011; a one-month gap in enrollment was 
allowed each year.  
Exclusion Criteria. Children with other forms of health insurance were excluded 
to ensure that all health services received by subjects were completely represented in 
Medicaid claims. Additionally, children with receipt of 6 or more chronic blood 
transfusions in a year were excluded since chronic transfusions are likely to be 
indicative of prior stroke or treatment for children with high blood velocities as detected 
by previous TCD.24,30 Blood transfusions were identified through CPT codes of 09882, 
09883, 36430, 36455, 86999, S3906, or S9538 on any claim. Children with 
missing/unknown race or date of birth information were also excluded. 
Missed Opportunities for TCD Screening 
Two outcomes were identified for each year the child was in the study population: 
1) receipt of at least one TCD screening and 2) presence of a missed opportunity for 
TCD screening. Receipt of TCD screening was defined as having any claim with a CPT 
code of 93886, 93888, 93890, 93892 or 93893.60 The proportion of children receiving 
TCD screening was calculated annually across the study period (2007 to 2011) and by 
age groups of 2-6 years, 7-11 years, and 12-16 years. A missed opportunity was 
defined as having an SCD-related healthcare encounter with no receipt of TCD 
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screening within the same year as defined in a prior study.61 An SCD-related healthcare 
encounter was defined as having an ED, inpatient or outpatient visit with an ICD-9 CM 
diagnosis code for SCD; children with no SCD-related visits were excluded in the 
consideration of missed opportunities. Consistent with other studies and in an attempt to 
capture all SCD-related claims, we included diagnosis codes for sickle cell anemia 
(282.60, 282.61, 282.62) and Hb S/β0 Thalessemia (282.41 and 282.42), as well as Hb 
SC (282.63, 282.64), Hb SD (282.68, 282.69).62-64 The proportion of missed 
opportunities was calculated annually, for the overall study period, and by age group. 
The maximum potentially achievable TCD screening rate was estimated for 25%, 50%, 
75% and 100% potential reductions in missed opportunities based on TCD screening 
rates and missed opportunities in 2011. For example, if 300 children were eligible to 
receive TCD screening, 200 children had a missed opportunity and 40 received TCD 
screening within a year (TCD screening rate of 40/300 =13%), a 25% reduction in 
missed opportunities would correspond to an additional 50 children receiving screening 
in that year. A total of 90 children would then receive screening, corresponding to a 
screening rate of 30% (90/300). 
Correlates of Missed Opportunities 
We investigated the correlates associated with a missed opportunity for TCD 
screening, including: SCD comorbidities (i.e. hypertension, pneumococcal infection, 
severity of disease41), SCD-related healthcare encounters (i.e. ED, inpatient, outpatient 
and hematologist visits, previous receipt of TCD screening), and demographics of age, 
sex, and sickle cell type. These comorbidities and healthcare encounters may provide 
more opportunities to recommend TCD screening and be associated with less missed 
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opportunities. This phase of the study was restricted to the subset of children 
continuously enrolled for at least two years (with allowance for a one month gap each 
year) to assure the covariates occurred prior to the missed opportunity (i.e., to preserve 
the temporal relationship). With the exception of age, all correlates were characterized 
in the first year of continuous enrollment and the presence of a missed opportunity was 
assessed in the following year (year 2 of continuous enrollment). Children with no SCD-
related healthcare encounters in year 2 were excluded from this analysis. 
SCD Comorbidities. SCD comorbidities were determined from Medicaid 
administrative claims. Hypertension was indicated by having claims for hypertension 
medications (drugs in antihypertensive class, excluding Clonidines), an inpatient or 
outpatient visit for hypertension as identified by claims with an ICD-9 diagnosis code of 
401-405, 997.91, or 796.2, or both.65,66 Pneumococcal infection was identified as any 
non-preventive healthcare claim with an ICD-9 code of 038.0, 038.2, 481, 482.3, 482.9, 
or 486. A proxy for severity of disease was determined using the number of inpatient 
visits per year with children with two or more inpatient visits considered to have greater 
severity of disease as compared to children with less than two visits.41  
SCD-Related Healthcare Encounters. ED, inpatient and outpatient (both 
preventive and non-preventive) visits were identified using the ICD-9 CM codes for 
SCD. Hematologist visits were defined as having at least one visit with a hematologist 
as indicated through Medicaid claims. Hematologists were identified through: 1) 
pediatric hematologists from the American Medical Association (AMA) Masterfile, and 2) 
an internet search of pediatric hematologists; subsequently, all hematologists were 
verified as a board certified hematologist using the National Provider Index (NPI). 
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Previous receipt of TCD screening was identified through CPT codes for TCD as 
described above and also measured in year 1 of continuous enrollment.  
Demographics. Age and sex were from Medicaid eligibility files; age was 
determined as the child’s age on January 1st of the second year of continuous 
enrollment. Sickle cell type was defined as either Hb SS or Hb S/β0 Thalessemia using 
information obtained from Newborn Screening records.  
Statistical Analysis. Frequencies and percentages were determined for all 
demographics, SCD comorbidities, and SCD-related healthcare encounters. Logistic 
regression with generalized estimating equations (GEE) was used to estimate the 
association between each covariate and the presence of at least one missed 
opportunity. GEE models with robust standard errors were estimated to account for the 
correlation within children, as each child could contribute multiple two-year time 
intervals.67 Alternative functional forms for continuous variables were investigated by 
comparing models with indicator variables (based on quintiles of the distribution) versus 
continuous variables for SCD-related healthcare encounters or dichotomous versus 
continuous variables for SCD comorbidities. Based upon the Quasi-Akaike Information 
Criterion (QIC) for each model, we determined SCD-related inpatient visits, ED visits 
and age should be modeled as continuous variables, while SCD-related outpatient visits 
were modeled using indicator variable based upon quintiles (0-1 visits, 2 visits, 3 visits, 
4-5 visits, 6+ visits).67 Hematologist visit, pneumococcal infection, and hypertension 
were included as dichotomous variables in addition to sickle cell subtype (Hb SS versus 
Hb S/β0 Thalessemia), sex (males versus females), severity of disease, and previous 
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receipt of TCD screening. Covariates showing an association (p<0.20) with presence of 
a missed opportunity were included in the final multivariable model. 




A total of 989 children born between 1987 and 2008 with SCD were identified in 
Michigan Medicaid claims from 2007-2011. Among these children, 6.4% percent were 
missing race and date of birth and 19.5% were not continuously enrolled for at least one 
year across the study period. In total, 329 (33%) met additional eligibility criteria (2-16 
years old, less than 6 blood transfusions in a year), contributing 1,024 person-years to 
this analysis. At baseline (2007), 224 children were continuously enrolled and met 
eligibility criteria as outlined above. Subsequent years included 216 (2008), 209 (2009), 
195 (2010) and 180 (2011) children. Among all 329 eligible children, 73 contributed 1 
year of enrollment (22%), 59 children contributed 2 years (18%), 53 contributed 3 years 
(16%), 46 contributed 4 years (14%) and 98 contributed 5 years of enrollment (30%). 
The average age in 2007 was 10.5 years (Standard Deviation (SD) 4.1), 50% were 
female and 87% were sickle cell subtype Hb SS (table 2.1). 
TCD Screening and Missed Opportunities 
Overall, 140 of 329 eligible children (49%) received screening at least once from 
2007 to 2011. Receipt of TCD screening was low each year (10% to 31%), although the 
proportion of children receiving TCD screening did increase over the study period 
(figure 2.1). Younger children ages 2-6 years had the highest likelihood of screening 
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(36%), and rates decreased with increasing age; 20% of children 7-11 years and 14% of 
12-16 years received screening from 2007 to 2011. 
The number of SCD-related healthcare visits was relatively constant from 2007 to 
2011. Each year, children averaged approximately 1 SCD-related inpatient visit, 3 SCD-
related outpatient visits, and less than one ED visit (table 2.2). Approximately 12-15% of 
children did not have an SCD-related healthcare encounter within each year and were 
excluded from further analysis, resulting in 197 (2007), 188 (2008), 177 (2009), 168 
(2010) and 158 (2011) children eligible for quantification of missed opportunities. 
The frequency of missed opportunities was high among children without a TCD 
and having at least one SCD-related healthcare encounter in a given year, ranging from 
64% to 89%; 76% of all person-years contained a missed opportunity (figure 2.2). The 
likelihood of a missed opportunity increased with increasing age, with 59% of children 
ages 2-6 years, 77% of children 7-11 years and 84% of 12-16 years having at least one 
missed opportunity over the study period.  
Increasing Screening Rates through Reduction of Missed Opportunities 
 An increase in TCD screening rates could be attained through reductions of 
missed opportunities. Based on 2011 rates (68% of children had a missed opportunity; 
28% of children received TCD screening), a 25% reduction in missed opportunities 
could correspond to a 42% TCD screening rate among children with SCD. Similarly, a 
reduction in missed opportunities by 50% could lead to a TCD screening rate of 57%; 
75% to a screening rate of 72%, and complete elimination of missed opportunities could 
lead to a screening rate of 93%. 
Correlates of Missed Opportunities 
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A subset of 270 children (82%) met eligibility criteria previously stated and were 
continuously enrolled for at least 2 years; 27 (10%) were excluded due to no SCD-
related healthcare encounter in the second year of eligibility, resulting in a population 
ranging from 171 (2007 to 2008) to 146 (2010 to 2011) for this phase of the study. SCD-
related healthcare encounters and presence of SCD comorbidities were relatively 
constant from 2007-2011; the majority had at least one hematologist visit in the first 
year of continuous enrollment, 10-20% had a pneumococcal infection, and 1-3% had a 
claim for hypertension medication or a hypertension visit (Table 2.3). Presence of a 
missed opportunity was associated with age, previous receipt of TCD screening, 
outpatient visits, inpatient visits, pneumococcal infection, hematologist visit, subtype and 
severity of disease. When these covariates were included in the multivariable logistic 
regression GEE model, a one year increase in age was associated with an increased 
likelihood of a missed opportunity (OR 1.11, CI 1.06, 1.15). Children with previous 
receipt of TCD screening (OR=0.23, CI: 0.15, 0.38) were less likely to have a missed 
opportunity than those without a previous screening, along with children with 4-5 
outpatient visits (OR=0.44, CI: 0.23, 0.83) or 6 or more outpatient visits (OR=0.25, CI: 
0.13, 0.49) compared to children with 0-1 outpatient visits (table 2.4). 
 
2.4 Discussion 
TCD screening rates were low in children with SCD in the Michigan Medicaid 
population, although rates increased over the study period. Low rates of screening 
combined with frequent interactions with the healthcare system led to a high frequency 
of missed opportunities for screening, particularly in older children. This study suggests 
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that even small reductions in missed opportunities could increase TCD screening rates 
substantially. We estimated that TCD screening rates could potentially more than triple 
if all missed opportunities were eliminated. 
TCD screening rates were low across all ages (10 to 31% from 2007 to 2011), 
but particularly in teenagers, with only 17% of children ages 12-16 years receiving 
screening over the study period. Previous studies in sickle cell centers have 
demonstrated higher overall rates of TCD screening, although a study in a large, 
managed healthcare plan also showed a trend toward increased screening rates in 
younger compared with older children. 41,42,45 Our results may be a more accurate 
reflection of screening rates in all children with SCD due to our inclusion of children up 
to the age of 16 years, consistent with NHLBI recommendations.25 Additionally, several 
studies have used administrative claims for SCD or a recent comprehensive visit for 
SCD to identify their study populations which biases towards those who seek care and 
thus may be more likely to receive screening. We included children with minimal or no 
healthcare for SCD in our calculations by identifying children with SCD through 
Newborn Screening records, which likely contributed to our lower rates as compared to 
other studies. 
High SCD-related healthcare utilization in Michigan coupled with low rates of 
TCD screening led to a high frequency of missed opportunities for TCD screening in 
children with SCD. The increase in missed opportunities in older children may be due in 
part to variation across guidelines in the ages recommend for TCD screening, which 
may create confusion for clinicians in regard to screening. While the NHLBI 
recommends screening from ages 2-16, the American Heart Association (AHA) 
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suggests screening begin at 2 years with more frequent screening in younger ages, with 
no specific guidelines for teenagers, and the AAP advises discussion of TCD screening 
for children ages 1-13 if available.25,37,39 Our results demonstrating an association 
between prior receipt of TCD screening and a decreased odds of a missed opportunity 
also indicate that the same children may be receiving TCD screening each year. These 
children may have physicians who are consistently recommending TCD screening or 
there may be other factors, such as patient knowledge of TCD screening, clinic specific 
recommendation practices, or review of medical chart indicating previous receipt of 
screening leading to more consistent screening. 
We hypothesized that increased ED, inpatient, outpatient and SCD visits and 
SCD comorbidities would be associated with fewer missed opportunities; however, no 
associations were found between these potential correlates and missed opportunities, 
besides with increased outpatient visits. Our association between missed opportunities 
and increased frequency of outpatient visits is similar to a recent study that showed 
children with one or more outpatient visits are 2-3 times more likely to receive TCD 
screening than children without an outpatient visit; however, we did not show a 
reduction in the odds of a missed opportunity until at least 4 outpatient visits.45 
Other unmeasured factors, such as physician and patient barriers, could be playing a 
role in missed opportunities aside from the factors investigated in this study. Lack of 
knowledge and/or awareness regarding TCD screening guidelines among physicians 
could be contributing to under recommendation for TCD screening and therefore missed 
opportunities.68 Patient barriers such as distance to a TCD screening facility and 
appointment adherence could also play a role in receipt of TCD screening, regardless of 
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physician recommendation.41,42,47 Furthermore, caregivers of children with SCD have 
been shown to perceive the stroke risk for their child to be low and may not realize the 
importance of TCD screening.46 Additional research is needed to explore provider and 
patient-level factors that may influence missed opportunities to identify the most viable 
intervention targets in this high-risk population. 
Strengths of this study include identification of the study population using 
Newborn Screening records. This allows us to not only identify children with SCD using 
the gold standard of blood testing, but also allows inclusion of children with no SCD-
related healthcare encounters (12-15% per year), which is not possible with children 
identified with claims data only. Use of the missed framework opportunity framework to 
identify opportunities for improvement in TCD screening rates is also novel. This 
framework has been utilized successfully in the immunization literature to identify 
interventions to increase screening rates,53,69 but to our knowledge, has never been 
explored in relation to TCD screening in children with SCD. Additionally, the criteria of 
full enrollment in Michigan Medicaid and no other forms of health insurance through all 
parts of the studies ensures full claim history is available for children in the study 
population. 
Limitations to this study also exist. Medicaid claims data were used to identify 
covariates, including SCD-related healthcare encounters and receipt of TCD screening; 
therefore, errors in CPT or ICD-9 codes could lead to potential misclassification of these 
variables. Additionally, if the screening was performed but the child’s insurance was not 
billed for the TCD screening, receipt of TCD screening would have been under reported, 
resulting in an overstatement of missed opportunities. Our definition of a missed 
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opportunity cast a wide net and may have not been representative of all situations in 
which a TCD would normally be ordered. Use of administrative data in this study 
allowed us to identify receipt of TCD screening, but we were unable to identify reasons 
for the missed opportunity. Although not all children with SCD are enrolled in Michigan 
Medicaid, 70% of children with SCD born 1987 to 2008 had a Medicaid ID, indicating 
that this data does capture the majority of children with SCD in Michigan. Finally, there 
may be additional children with SCD in Michigan not identified through Michigan’s 
Newborn Screening program; however, through the use of Newborn Screening records, 
we can accurately report that each child included in the study population did have SCD. 
In conclusion, the proportion of children receiving TCD screening each year is 
low, and missed opportunities are numerous in children with SCD in the Michigan 
Medicaid population. Increasing age is associated with having a missed opportunity, 
while 4 or more SCD-related outpatient visits and receipt of TCD screening in the year 
prior are protective against missed opportunities. Reduction of missed opportunities for 
TCD screening may be an integral strategy to increase adherence to TCD screening 
recommendations, thereby reducing the incidence of pediatric stroke in this high-risk 
population.   
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Table 2.1 Baseline Demographics of Children with 
Sickle Cell Disease Continuously Enrolled in 
Michigan Medicaid in 2007, n=224 
 
N (%) or Mean (SD) 
Age on 1/1/2007 (years) 9.7 (4.2) 
Sex 
     Male 98 (50%) 
   Female 97 (50%) 
Race 
     Black 193 (99%) 
   White 2 (1%) 
Sickle Cell Subtype 
     Hb SS 169 (87%) 






Table 2.2 Healthcare Encounters Among Children with Sickle Cell Disease in 




n = 224 
2008 
n = 216 
2009 
n = 209 
2010 
n = 195 
2011 
n = 180 
SCD-Related Visit Mean (SD) 
Inpatient 1.2 (1.8) 1.2 (1.9) 1.4 (2.0) 1.1 (1.8) 1.2 (1.9) 
Outpatient 3.3 (3.4) 3.4 (3.3) 3.9 (3.7) 3.7 (3.6) 3.7 (3.6) 
Emergency Department 0.7 (1.3) 0.7 (1.4) 0.8 (1.3) 0.9 (1.4) 0.8 (1.4) 
 
N (%) 




Table 2.3. Healthcare Encounters and Comorbidities of Children with Sickle Cell 
Disease Continuously Enrolled in Michigan Medicaid for at least 2 years from 2007 
to 2011 and with at least 1 Sickle Cell Disease-Related Healthcare Encounter* 
SCD-Related Visits 
2007-2008 
n = 171 
2008-2009 
n = 156 
2009-2010 
n = 153 
2010-2011 
n = 146 
 
Mean (SD) 
Inpatient 1.3 (1.7) 1.4 (1.8) 1.4 (1.7) 1.3 (1.9) 
Outpatient 3.7 (3.5) 4.0 (3.2) 4.1 (3.5) 4.3 (3.6) 
Emergency Department 0.7 (1.3) 0.6 (0.9) 0.8 (1.2) 1.0 (1.5) 
 
N (%) 
Pneumococcal Infection 20 (12%) 27 (17%) 30 (20%) 17 (12%) 
Hematologist Visit 151 (88%) 133 (85%) 123 (80%) 119 (82%) 
Hypertension Visit 1 (1%) 2 (1%) 0 (0%) 5 (3%) 
Hypertension Medication 2 (1%) 2 (1%) 2 (1%) 2 (1%) 
Severe SCD 59 (35%) 52 (33%) 59 (39%) 45 (31%) 










Table 2.4. Multivariable Associations with Presence of a Missed Opportunity for 
Transcranial Doppler Screening in Michigan Medicaid from 2007 to 2011, n =243 
  
Odds 
Ratio Confidence Interval 
SCD-related Outpatient Visits 0-1 visits Reference Reference 
 
2 visits 0.98 0.45, 2.13 
 
3 visits 0.69 0.33, 1.42 
 
4-5 visits 0.44 0.23, 0.83 
 
6+ visits 0.25 0.13, 0.49 





1.11 1.06, 1.15 
Inpatient SCD visit 
 
0.92 0.78, 1.09 
Pneumococcal Infection Yes 0.83 0.47, 1.45 
 
No Reference  
Hematologist Visit Yes 0.85 0.41, 1.76 
 
No Reference  
Severity Yes 1.56 0.80, 3.03 
 
No Reference  
Sickle Cell Subtype Hb S/β0 Thalessemia 1.39 0.76, 2.54 
 




Figure 2.1 Receipt of Transcranial Doppler Screening Among Children with Sickle 
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Figure 2.2 Frequency of Missed Opportunities In Children Continuously Enrolled 
in Michigan Medicaid for at least 1 year from 2007 to 2011 with Sickle Cell Disease 
and at least 1 Sickle Cell Disease-Related Healthcare Encounter 
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Aim 2: The Role of Neighborhoods in the Receipt of Transcranial Doppler 
Screening Among Children with Sickle Cell Disease
 
3.1 Introduction  
Sickle cell disease (SCD) is a chronic condition causing significant morbidity and 
mortality exclusively in minority children and is associated with an elevated risk of 
stroke.16,17,70 TCD screening is used in these children to detect high blood flow velocities 
in cerebral vessels which indicate an increased stroke risk and signal the need to initiate 
chronic blood transfusions as a key stroke prevention strategy.24,30,32 Once transfusions 
are initiated, stroke incidence is reduced by up to 90% relative to standard medical care 
as shown in the 1998 Stroke Prevention Trial in Sickle Cell Anemia (STOP) study. 24 
Although chronic blood transfusion has been known to be an effective stroke 
prevention strategy since the late nineties, TCD screening rates continue to be low, and 
few individual-level characteristics impacting screening rates have been identified.41-43,45 
Neighborhood factors have been shown to influence health status among children with 
chronic conditions; these factors may also influence TCD screening among children with 
SCD, although this has not yet been explored.71-73 Neighborhood effects may impact 
TCD screening through multiple pathways. Residing in a socioeconomically 
disadvantaged neighborhood has been shown to reduce the likelihood of having a 




that residents of those neighborhoods are unable to obtain healthcare when 
necessary.74 Living in a disadvantaged neighborhood leads to higher levels of stress, 
which is associated with lack of receipt of preventive care.74 Increased stress is, in turn, 
connected with depression, anxiety, distress and feelings of powerlessness, all of which 
may decrease the likelihood of receipt of TCD screening.75 Individuals residing in 
disadvantaged neighborhoods may be less likely to participate in health related 
behaviors due to lower levels of social support.76,77 Conversely, utilization of preventive 
services has been shown to be positively correlated with the racial and ethnic 
composition of the neighborhood.78 For example, neighborhoods with a greater 
concentration of African Americans may have increased TCD screening rates compared 
to neighborhoods with a lesser concentration of African Americans due to the sharing of 
health related information about SCD given that it predominantly affects those 
populations. 
Identification of neighborhood factors influencing TCD screening could inform the 
utility of community-level interventions to improve screening rates among children with 
SCD. With this in mind, our objective was to investigate the geographic variability in 
TCD screening rates and the role of neighborhood factors in the receipt of TCD 
screening among children with SCD. We hypothesized there would be a spatial pattern 
of TCD screening rates across neighborhoods and that living in a socioeconomically 
disadvantaged neighborhood would be associated with lack of TCD screening. 
However, the proportion of African American residents within a neighborhood would be 






We used data from Michigan Medicaid to identify presence of a spatial pattern 
and association of neighborhood-level factors in the receipt of TCD screening among 
children with SCD residing in Wayne County, Michigan. A large proportion of the county, 
which includes the City of Detroit, is African American and is home to the majority of 
children with SCD. 
Study Population 
Our study population focused on children 2 to 16 years with SCD who resided in 
Wayne County Michigan. We queried administrative data (inpatient/outpatient claims, 
enrollment data) from Michigan Medicaid for the years 2007 to 2011 from the MDCH 
data warehouse. All states perform newborn screening (NBS) to facilitate early 
identification of SCD upon birth. Using birth certificates, Michigan Medicaid data was 
linked to NBS data to identify children with SCD.59 
Inclusion Criteria. We included children with at least one year of continuous 
enrollment in Michigan Medicaid from January 1st through December 31st from 2007 to 
2011 and no other forms of health insurance within this time frame. An allowance for a 
one-month gap in enrollment each year was made. The addresses for children on 
January 1st of each year of continuous enrollment were obtained from Medicaid 
enrollment files. All addresses were geocoded and tied the census tract using 
geographic identifiers. We included only children with residence in Wayne County, 
Michigan. We included children ages 2 to 16 years old with hemoglobin (HgB) SS or 
HgB S/β0 Thalessemia based on current recommendations for TCD screening from the 




Exclusion Criteria. To exclude children with a potential prior stroke or who were 
under current treatment for high blood velocities as detected by previous TCD, children 
with receipt of 6 or more chronic blood transfusions (CPT codes of 09883, 36455, 
86999, S3906, S9538, 09882 or 36430 on any inpatient or outpatient claim) in a year 
were excluded.24,30 Children missing date of birth information were also excluded. 
TCD Screening and Neighborhood Characteristics 
Receipt of TCD screening (yes/no) was defined for each child during each year 
of continuous enrollment as having any claim with a CPT code of 93866, 93888, 93890, 
93892 or 93893.60 Neighborhoods were defined as census tracts, which have been 
shown to contain generally consistent measures of socio-demographic characteristics of 
the residents.79 Neighborhood characteristics from the American Community Survey 
(ACS) 5 year estimates (2007 to 2011) were linked by census tract to children meeting 
study eligibility criteria. Neighborhood characteristics considered included the census 
tract-level percent unemployment, percent African American residents, percent less 
than high school education and median household income.71,73 
Statistical Analysis 
Frequencies and percentages were determined for demographics of children in 
the study population and for receipt of TCD screening each year. Means and standard 
deviations of neighborhood socio-demographic characteristics were calculated across 
census tracts. The tract-level TCD screening rate was calculated as the total number of 
person-years containing TCD screening divided by the total number of person-years of 
children with SCD eligible for screening within each tract. We investigated tract-level 




measures spatial correlation and allows evaluation of a spatial pattern across census 
tracts (i.e., census tracts in close proximity have similar TCD screening rates than those 
further away).81 Logistic regression with GEE was used to estimate the association 
between each neighborhood-level factor and receipt of TCD screening, adjusted for age 
as a continuous variable. The GEE framework was conducted to account for the 
correlation within children, as each child could contribute multiple person-years. The 
model used an exchangeable correlation structure and robust standard errors to assess 
significance.82 Independence was assumed for children in the same census-tract, as the 
small number of person-years within each tract made estimation of within-tract 
correlation unfeasible.83 Statistical analyses were performed with SAS 9.2 and ArcGIS 
10.1, which was also used for mapping purposes. 




A total of 989 children with SCD born between 1987 and 2008 were identified in 
Michigan Medicaid claims from 2007 to 2011. Six percent were excluded for missing 
birthdate or race and 19.5% had no years of continuous enrollment from 2007 to 2011. 
In total, 329 (33%) met eligibility criteria; 176 of the 329 (54%) children resided in 
Wayne County during the study period and were included in the analysis. These 
children collectively contributed 532 person-years. The average age in 2007 was 10.8 




Hb SS (table 3.1). The proportion of children receiving TCD screening increased from 
2007 to 2011, ranging from 7 to 36% (figure 3.1). 
Children in the study population resided in 141 census tracts in Wayne County. 
Mean percentage of African American residents in the census tract was 80% (SD 28%), 
percentage of residents with less than a high school education was 27% (SD 18%), 
percentage unemployed was 27% (SD=10%), and the mean household income was 
$31,040 (SD $12,091). Number of person-years within each census tract ranged from 1 
to 14, with a median of 3 (Interquartile Range (IQR) 2 to 5). The proportion of children 
receiving TCD screening within census tracts ranged from 0 to 100%, with a median of 
0% and a mean of 19% (SD 29%, IQR 29%) (Figure 3.2). Overall, 60% of 
neighborhoods (n=85) had screening rates of 0%, and 71% (n=114) had screening 
rates less than 50%. Investigation of spatial correlation failed to provide any evidence of 
a spatial pattern of TCD screening across the census tracts in Wayne County (Moran’s I 
z-score -0.94, p-value 0.35). No associations were found between the neighborhood 
characteristics and receipt of TCD screening among children with SCD (Table 3.2). 
 
3.4 Discussion 
TCD screening rates in Michigan are low among children in Wayne County, 
Michigan (7 to 36%) and across census tracts in Wayne County, show no spatial 
pattern, and were not found to be associated with neighborhood socio-demographic 
characteristics. The lack of variability in screening rates across neighborhoods may 




opposed to particular neighborhoods are necessary to increase TCD screening rates in 
this high-risk population. 
The lack of association between neighborhood characteristics and TCD 
screening in our study population may be partially due to the low TCD screening rates 
and high levels of neighborhood disadvantage in Wayne County. TCD screening rates 
were low across all census tracts, with a median of 0%. Additionally, the socioeconomic 
characteristics of the neighborhoods where children with SCD resided were indicative of 
a high level of disadvantage. Using American Community Survey 2007 to 2011 
estimates, the mean rate of unemployment across our census tracts in Wayne County 
was 27% versus 8.7% in the US, median household income was $31,040 versus 
$52,762 in the US, and the mean percentage less than high school education was 27% 
in our census tracts versus 8.5% in the US.84 These neighborhoods are also more 
disadvantaged than Wayne County as a whole, an area reflective of other urban 
populations with a large percentage of African Americans, reporting nearly 10% higher 
unemployment (Wayne County: 17.4%), $10,000 lower median household income 
(Wayne County: $41,886), and 16% less residents with less than a high school 
education (Wayne County: 11.5%). These statistics show the census tracts where 
children with SCD reside in Wayne County are at a severe socioeconomic disadvantage 
compared to the rest of the US. 
Strengths of this study include identification of the study population using 
Newborn Screening records. This allowed us to identify children with SCD using the 
recognized gold standard, blood testing, along with the criterion of continuous 




limitations to this study. Addresses of children were assessed on January 1st of each 
year of continuous enrollment. Children may have moved in or out of Wayne County 
within the year, and been inappropriately included, excluded, or attributed to the 
incorrect neighborhood based on their address. Identification of neighborhoods using 
census tracts is a crude measure of neighborhood and may not be reflective of the true 
boundaries that define the residence of children with SCD. The ACS estimates used 
may introduce bias as 5 year estimates were used. These estimates refer to the socio-
demographic characteristics over the entire study period and may not be reflective of 
the tract-level characteristics each year. The neighborhood variables in this analysis 
may not have accurately captured the socio-cultural and economic variability of the 
neighborhoods. Additional neighborhood variables may influence TCD screening, such 
as availability of medical resources, neighborhood safety, and reliability of public 
transportation, which were not considered. Additionally, receipt of TCD screening was 
determined using Medicaid administrative claims, which may be incomplete and/or 
inaccurate. Only children enrolled in Michigan Medicaid were included; however, 70% of 
children born in Michigan with SCD have a Medicaid ID suggesting these cases are 
generally representative of the population of children with SCD in Michigan. Further, the 
sample size was low for this study; adequate power to detect spatial correlation with this 
data may not have been present. 
In conclusion, our results did not show that neighborhoods play a role in the 
receipt of TCD screening among children with SCD in Wayne County enrolled in 
Michigan Medicaid, indicating that additional barriers to screening may exist among 




necessary. Strategies are clearly needed to improve the translation of the clinical trial 
evidence supporting TCD screening to the population in this geographic area to reduce 





Table 3.1. Baseline Demographics of Children with Sickle 
Cell Disease in Michigan Medicaid Continuously Enrolled 
for at least 1 Year from 2007 to 2011 and Residing in Wayne 




N (%) or Mean (SD) 
  Age on 1/1/2007 (years) 10.8 (4.0) 
  Sex 
      Male 63 (51%) 
     Female 60 (49%) 
  Sickle Cell Subtype 
      HgB-SS* 116 (94%) 
     HgB-Beta Thalessemia* 7 (6%) 






Table 3.2. Neighborhood Level Factor Associations with Receipt of Transcranial 
Doppler Screening Among Children with Sickle Cell Disease in Michigan Medicaid 
Residing in Wayne County, 2007 to 2011* 
 




% Unemployment 0.98 0.67, 1.43 
% African American Residents 0.97 0.82, 1.15 
% Less than High School Education 1.27 0.86, 1.86 
Median Household Income 0.97 0.70, 1.33 
*Adjusted for age 




Figure 3.1. Transcranial Doppler Screening Rates Among Children with Sickle 
Cell Disease Continuously Enrolled in Michigan Medicaid for at least one year 
from 2007 to 2011 and Residing in Wayne County 
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Figure 3.2. Tract-Level Transcranial Doppler Screening Rates in Wayne County, 








Aim 3: Factors Influencing Physician Adherence to 




Sickle cell disease (SCD) is a chronic condition with extensive morbidity that 
exclusively affects minority children and increases the risk of stroke, a leading cause of 
childhood death and disability.16,17,70 Historically, approximately 11% of children with 
SCD had a stroke by age 20; however, many of these strokes are now 
preventable.24,28,29,70 TCD screening is used to detect high blood flow velocities in 
cerebral vessels which indicate an increased stroke risk and signal the need to initiate 
chronic blood transfusions as a key stroke prevention strategy.24,30,32 The Stroke 
Prevention Trial in Sickle Cell Anemia (STOP), published in 1998, showed once 
transfusions are initiated, stroke incidence is sharply reduced by up to 90% relative to 
standard medical care.24 
Given its importance as a stroke prevention strategy, numerous national 
organizations have released guidelines recommending TCD screening among children 
with SCD. However, these guidelines differ substantially in key areas, with the NHLBI 
providing the most specific guidelines.25,37,39 Adherence to clinical practice guidelines 
has been demonstrated to be beneficial in improving health outcomes for patients 
across many specialties.85-89 Despite these findings, physician adherence to guidelines 




differences in these guidelines may lead to variability in physicians’ recommendation of 
TCD screening among children with SCD, as suggested by the low rates of screening 
observed in numerous settings.41-43,45 
Importantly, children with SCD have significantly higher healthcare utilization 
than children without SCD, indicating that opportunities for recommending TCD 
screening exist.20 Because the degree of physician adherence to TCD screening 
guidelines may influence screening rates, our objective was to explore factors that may 
be related to adherence such as physicians’ awareness, attitudes and knowledge of 
TCD screening guidelines for children with SCD. We also assessed physician-perceived 
external barriers to administration of TCD screening in children with SCD among 




Pediatric hematologists, pediatric neurologists and primary care physicians 
(PCPs) were chosen as the study population as these physicians would be most likely 
to treat children with SCD. Pediatric hematologists and pediatric neurologists (n=250 
each due to cost limitations) were randomly sampled across the US (due to insufficient 
numbers of these specialties in the state of Michigan) from the American Medical 
Association (AMA) Physician Masterfile. The AMA Masterfile is a continuously updated 
list of all physicians in the US which includes both members and nonmembers of the 
AMA. PCPs were identified as physicians with a certification in general pediatrics, family 




of the physician treating a child with SCD, PCPs were included if they had one or more 
Michigan Medicaid claims reporting an ICD-9 CM diagnosis code for SCD from 2008-
2012 (n=206). Consistent with other studies, we included diagnosis codes for sickle cell 
anemia (282.60, 282.61, 282.62), Hb SC (282.63, 282.64), Hb SD (282.68, 282.69), and 
Hb S beta thalassemia (282.41 and 282.420); we did not include cases reporting sickle 
cell trait (282.5) or other hemoglobinopathies.62-64 Medicaid claims for states other than 
Michigan were not available to identify physicians treating children with SCD in these 
states. 
Survey Development, Content and Administration 
The physician survey was developed by the lead author and revised based on 
input from the research team. Elements of the survey were chosen based off the 
framework presented by Cabana et al, which organized physician barriers into seven 
major categories.95 Our survey content was developed based on factors hypothesized 
to influence physician adherence to TCD guidelines specifically and included the 
following: physician (internal) barriers (awareness, attitudes and knowledge of 
guidelines), physician-perceived external barriers, and physician and practice 
characteristics (figure 4.1, adapted from Cabana et al).95 Our full survey instrument is 
provided in Appendix 4.1. 
Awareness of TCD screening guidelines was assessed through questions about 
familiarity and accessibility of national guidelines for TCD screening. Attitudes regarding 
TCD screening for children with SCD were assessed through agreement with a series of 
statements regarding outcome expectancy (SCD stroke risk, predictive value of TCD 




conflicting guidelines), and self-efficacy (comfort caring for children with SCD and with 
TCD screening, ability to reduce stroke risk). Knowledge of TCD screening guidelines 
for children with SCD was assessed through a series of multiple choice and open ended 
questions regarding types of SCD to be included for screening, ages to initiate and 
terminate screening, and actions to take based on TCD screening results. Correct 
responses to knowledge questions were based on agreement with NHLBI guidelines for 
treatment of children with SCD, as these guidelines are the most specific regarding TCD 
screening among children with SCD and are often used as guidelines for clinics 
developing TCD screening programs.25,55 Physician-perceived external barriers to TCD 
screening focused on agreement with statements in three main areas: 
access/environmental barriers, patient barriers and administrative barriers. Level of 
agreement with each attitude and external barrier statement was assessed using a 5-
point Likert scale: strongly disagree (1) to strongly agree (5). Physician and practice 
characteristics were assessed through multiple choice and open ended questions 
regarding physician sex, race, ethnicity, age, years of practice, specialty, hours of 
general continuing medical education, patient characteristics, and practice affiliation. 
The survey was piloted for content and clarity with at least one physician from 
each specialty and questions were modified prior to administration based on feedback. 
The survey was administered via priority mail in May 2012 with a $2 incentive included. 
A follow-up mailing was conducted among non-respondents without an incentive in 





Physicians in the study population were eligible to complete the survey if the 
survey was deliverable and if they indicated on the survey that s/he currently provided 
care for children with SCD. All eligible physicians were asked to answer questions 
regarding attitudes and perspectives on TCD screening and physician and practice 
characteristics. Physicians who believed patients with SCD should receive TCD 
screening (92%) were then asked to answer questions regarding knowledge of specific 
guidelines and physician perceived external barriers, as these physicians would be the 
most appropriate recipients of interventions aimed at increasing adherence to screening 
guidelines. 
Statistical Analysis 
Means and standard deviations (SD) or frequencies and percentages were 
calculated for physician and practice demographics. Responses regarding attitudes 
toward guidelines regarding TCD screening and external barriers were collapsed into 
categories of agree (strongly agree or agree) or disagree (strongly disagree, disagree, 
neutral) and compared across specialties using chi-square tests. Knowledge of specific 
NHLBI guidelines was calculated as the proportion of questions answered correctly (6 
knowledge questions were included in the survey) and compared across specialties 
using Fisher’s exact tests due to small sample size. Frequencies of responses for all 
other questions were calculated overall and by specialty. 







A total of 706 physicians were sent surveys; 65 were undeliverable, 8 physicians 
had retired, and 276 were returned by the respondent (44% response rate among 
deliverable surveys). Among the 276 respondents, 141 (51%) physicians currently 
treated children with SCD (28% PCPs, 21% pediatric neurologists, and 51% pediatric 
hematologists). Among these physicians, 61% were male, 73% were white, 18% Asian 
or Pacific Islander, 4% black, and 4% other, and 4% were of Hispanic origin. The 
average respondent was 52 years old (Standard Deviation (SD) 11 years) and had been 
practicing for 19 years (SD 12 years). The respondents varied by self-reported hours of 
general continuing medical education per month, the proportion of pediatric patients 
with SCD, the proportion of pediatric patients covered by Medicaid, and number of 
pediatric patients seen per year; the majority (66%) worked at a university, hospital or 
medical center (Table 4.1). Overall, 127 (92%) out of the 141 respondents who treat 
children with SCD believed that children with SCD should receive TCD screening (82% 
PCPs, 90% pediatric neurologists, 99% pediatric hematologists) and of these, 97 (72%) 
currently recommend screening to their patients (34% PCPs, 64% pediatric 
neurologists, 94% pediatric hematologists). Reasons for not recommending TCD 
screening included referring the patient to a hematologist (n = 17), another doctor (n = 
2) or a sickle cell center (n = 4) for screening, or lack of familiarity with guidelines (n = 
6). 
Internal Barriers - Awareness 
Sixty-seven percent of eligible respondents indicated they were extremely, very, 
or moderately familiar with national guidelines regarding TCD screening among children 




across specialty, with 30% of PCPs, 61% of pediatric neurologists and 90% of pediatric 
hematologists indicating they were extremely, very or moderately familiar with TCD 
screening guidelines (p<0.0001). If more information was needed regarding TCD 
screening among children with SCD, 66% of respondents indicated they would refer to 
the AAP, 44% the NHLBI, 35% Up To Date Inc (an online, evidence-based clinical 
support resource), 26% the AAN, and 5% the AHA. Other sources of information 
included the American Society of Hematology (n = 5), other doctors or centers (n = 5) or 
research papers, textbooks, other websites or guidelines (n = 8). 
Internal Barriers - Attitudes 
Attitudes regarding TCD screening among children with SCD differed depending 
on the statement and among specialties. Table 4.2 lists each perspective statement, 
along with the proportion of physicians who agreed with the statement by specialty. 
Most physicians felt comfortable caring for children with SCD and believed these 
children have a high risk of stroke. Additionally, most had positive perceptions of 
guidelines with few indicating that guidelines were based on questionable evidence or 
that conflicting guidelines existed. The majority (64%) of PCPs did not feel well informed 
regarding TCD guidelines, whereas only 28% of pediatric neurologists and 7% of 
hematologists did not feel well informed (p<0.0001). Self-efficacy questions revealed 
similar specialty patterns, with PCPs feeling more uncomfortable discussing risks and 
benefits of TCD screening with patients and families and their ability to reduce stroke 
risk in patients with SCD in comparison to pediatric neurologists and hematologists. The 




abnormal TCD results (95% PCPs, 99% pediatric neurologists and 93% pediatric 
hematologists). 
Internal Barriers - Knowledge 
Among physicians who believe children with SCD should receive TCD screening 
(n=127), the proportion of knowledge questions answered correctly based on NHLBI 
guidelines was low. Overall, the question with the highest percentage of correct 
responses was the age to begin TCD screening (35% correct), and the lowest was 
actions to take upon an abnormal TCD screening result (13% correct). Percentage of 
correct responses differed among specialty, with PCPs and pediatric neurologists 
consistently scoring lower than pediatric hematologists (Table 4.3). 
External Barriers 
Two physician-perceived external barriers were reported by the majority of 
physicians to hinder receipt of TCD screening; distance to a vascular laboratory (51%) 
and low patient adherence to TCD appointments (56%). In general, PCPs selected 
more barriers than pediatric neurologists or hematologists. Physician-perceived external 
barriers differed across specialties for the majority of barriers (Table 4.4). 
 
4.4 Discussion 
Abnormal TCD results in children with SCD are associated with a high risk of 
stroke and should prompt stroke prevention efforts in the form of chronic blood 
transfusions. Although the effectiveness of blood transfusion for stroke prevention has 
been known since the late nineties, rates of TCD screening among children with SCD 




guidelines for children with SCD may influence physician recommendation of TCD 
screening; however, no study has investigated these internal factors. In our study, the 
majority of physicians believed children with SCD have a high risk of stroke and should 
receive TCD screening, but familiarity with guidelines, self-efficacy and knowledge of 
NHLBI-specific guidelines were low, particularly among PCPs, and differed considerably 
by specialty. Additionally, we identified distance from child’s home to a vascular 
laboratory and patient adherence to appointments as physician-perceived external 
barriers. 
Among attitudes regarding TCD guidelines, self-efficacy (comfort discussing risks 
and benefits of TCD screening and blood transfusions, ability to reduce stroke risk 
among patients) and outcome expectancy (TCD predicts stroke risk, blood transfusions 
reduce stroke risk) showed the largest specialty differences, with PCPs and pediatric 
neurologists consistently rating themselves lower in these categories than pediatric 
hematologists. However, the overall proportion of physicians with high self-efficacy and 
outcome expectancy was still low, indicating a need for improvement in these areas 
across all specialties. Interventions focusing on improving self-efficacy among 
physicians, such as educational toolkits, formal clinical training and increased 
availability of educational resources, have been successful in increasing confidence and 
knowledge among physicians across the board.68,96,97 As most physicians felt 
comfortable caring for children with SCD, these educational interventions might be best 
focused on increasing physician knowledge of the risks and benefits of TCD screening 
and blood transfusions, as these were areas in need of improvement among all 




released by the NHLBI which identified clear, evidence based guidelines for physicians 
as a priority,98 and numerous quality improvement collaborations focused on improving 
care and outcomes among children with SCD.99 Impacting attitudes through 
enhancement of knowledge and confidence may positively affect adherence to 
guidelines, especially among PCPs and pediatric neurologists, although this requires 
further study. 
With regard to knowledge, questions about next steps for abnormal TCD results 
were answered incorrectly with the highest frequency. This indicates the need for 
increased physician education regarding actions to take based on TCD screening 
results since these actions are the basis for stroke prevention efforts. Also, questions 
about ages to begin and end screening were answered incorrectly by the majority of 
respondents which could potentially lead to differential TCD screening rates by age. As 
hematologists’ knowledge and familiarity regarding guidelines was higher than 
neurologists and PCPs, increased referral by other physicians to hematologists could be 
an important driver of increased TCD screening. This may be especially true 
considering only one third of PCPs reported recommended screening to their patients 
and the majority of PCPs who did not recommend screening referred the patient to a 
hematologist for TCD screening. Since treatment guidelines for children with SCD 
recommend frequent contact with hematologists, patient adherence to these specialist 
appointments may be integral to increasing TCD screening rates. However, it may also 
be important to continue to increase knowledge of TCD guidelines among PCPs, as not 
all children will see a hematologist each year. Although hematologists did answer the 




answers among hematologists was low. There is still substantial room for improvement 
in their knowledge of specific guidelines, particularly if they are perceived as the primary 
initiator of TCD screening among children with SCD. 
Our survey showed the AAP to be the most common source referenced for 
information regarding TCD screening. These guidelines are the most ambiguous given 
their recommendation that TCD screening should be discussed, if available.39 While 
both the NHLBI and AHA strongly recommend TCD screening, their respective 
guidelines differ with regard to recommended ages for screening, frequency of 
screening and actions to be taken based on screening results.25,37 The AAP’s more 
ambiguous recommendation has provoked controversy among pediatricians who feel 
stronger guidelines are warranted.40 We used the NHLBI guidelines as the standard for 
knowledge which may have influenced our results with respect to the proportion of 
correct answers. These guidelines are used as the basis for TCD screening in 
numerous clinics.42,55 
Few studies exist regarding physician-perceived external factors that may 
influence TCD screening rates. We found that physicians perceive lack of adherence to 
appointments and distance to a vascular laboratory to be barriers to the receipt of TCD 
screening. Data from a recent study showed 72% of hematologists identified patient 
adherence to appointments to be a barrier to TCD screening.47 The finding that distance 
to a vascular lab may be a barrier is also supported by research in a large, managed 
healthcare plan that found living within 30 miles of a vascular laboratory was the only 
independent predictor for receipt of TCD screening.41 One option to address this 




hematology clinics, as this eliminates travel to a vascular laboratory and has been 
shown to increase screening rates.55 Although both this study and ours indicated that 
physicians perceive patient oriented issues to be the main barriers to receipt of TCD 
screening, lack of knowledge and self-efficacy are perceived by caregivers as greater 
barriers to screening than practical issues such as transportation and appointment 
adherence.46 The disagreement between patient and provider perceptions of barriers to 
TCD screening indicates that further study is necessary among both patient guardians 
and providers to identify which external factors influence screening rates in order to 
develop interventions that focus on the correct targets. 
Some limitations of this work warrant discussion. The main limitation for this 
study is the 44% response rate among physicians; however, this response rate is in line 
with other physician survey response rates.100-102 Non-response rates among 
deliverable surveys were similar across specialties, with 58% of PCPs, 58% of pediatric 
neurologists and 54% of pediatric hematologists not returning deliverable surveys. The 
AMA Masterfile as a source to identify all pediatric hematologists and neurologists in the 
United States may have been incomplete and not included all specialists. As the survey 
was focused on self-report, bias may exist on multiple aspects of the survey, such as 
awareness and attitudes regarding screening practices. Use of PCPs only in the state of 
Michigan may limit the generalizability. Also, we did not investigate physician initiation of 
blood transfusion for patients regardless of TCD screening. It is possible that some 
doctors begin stroke prevention efforts without prior use of TCD results, although this 
would not be consistent with current guideline recommendations. Given the results of 




physician adherence to guidelines, or other factors are contributing to the low screening 
rates; however, we were able to identify factors that may affect adherence for future 
intervention targets. 
Factors such as awareness, attitudes and knowledge of specific guidelines may 
influence physician adherence to TCD screening recommendations. Additional research 
regarding these barriers is necessary to understand their role in physician 
recommendation of TCD screening, specifically in the areas of physicians’ lack of self-
efficacy and knowledge of recommendations as we found these to be low across all 
specialties. This additional research could assist in the development of targeted 
interventions to increase TCD screening among children with SCD. As significant 
differences were found among specialties, specialty-specific education may be 
important to improve TCD screening rates; however, substantial room for improvement 
exists across all specialties. Targets for increasing TCD screening among children with 
SCD must continue to be identified in order to prevent the devastating consequences of 






Table 4.1. Characteristics of Physicians Treating Children with Sickle Cell 
Disease Responding to Survey, , n = 141 
 N (%) 
Sex Male 84 (60%) 
Female 53 (38%) 
   
Race White 99 (70%) 
Black 6 (4%) 
Asian / Pacific Islander 24 (17%) 
Other 6 (4%) 
   
Ethnicity Non-Hispanic 126 (89%) 
Hispanic 5 (4%) 
   
Age  52 (11) years 
Practice Years  19 (12) years 
   




Pediatric Neurology 29 (21%) 
   
Hours of CME per month* >1 hour 3 (2%) 
1-5 hours 81 (57%) 
More than 5 hours 55 (39%) 
   
Pediatric Patients 
With Sickle Cell 
Disease 
>5% 78 (55%) 
5-10% 24 (17%) 
11-20% 14 (10%) 
 More than 20% 22 (16%) 




>5% 7 (5%) 
5-24% 19 (13%) 
25-49% 41 (29%) 
 More than 50% 65 (46%) 
   
Primary Practice 
Ownership 
Private office 21 (15%) 
University/hospital/medical center 91 (65%) 
 Practice Network 10 (7%) 
 Sickle Cell Center 13 (9%) 
 Combination 2 (1%) 
   
Pediatric Patients 
Per Year 
1-500 34 (24%) 
501-1500 53 (38%) 
 1501-3000 37 (26%) 
 More than 3000 14 (10%) 




Table 4.2. Agreement with Physician Perceptions and Attitudes Regarding Transcranial Doppler Screening, n = 141 
 






n = 40 
Pediatric 
Neurology* 
n = 29 
Pediatric 
Hematology* 
n = 72 
p-value** 
I feel comfortable caring for children with sickle cell 
disease. 119 (86%) 28 (71%) 20 (71%) 71 (99%) <0.001 
Children with sickle cell disease have a high risk of stroke. 130 (93%) 34 (87%) 29 (100%) 67 (93%) 0.13 
I do not feel well informed regarding Transcranial Doppler 
ultrasonography guidelines for children with sickle cell 
disease. 
38 (27%) 25 (64%) 8 (28%) 5 (7%) <0.001 
I do not feel comfortable discussing risks and benefits of 
Transcranial Doppler ultrasonography with my patients and 
their families. 
36 (26%) 21 (54%) 7 (24%) 8 (11%) <0.001 
Guidelines for Transcranial Doppler ultrasonography for 
children with sickle cell disease are based on questionable 
evidence. 
7 (5%) 5 (13%) 0 (0%) 2 (3%) 0.02 
There are conflicting guidelines regarding Transcranial 
Doppler ultrasonography for children with sickle cell 
disease. 
15 (11%) 7 (18%) 3 (10%) 5 (7%) 0.18 
Transcranial Doppler ultrasonography results predicts 
stroke risk. 96 (69%) 14 (37%) 17 (59%) 65 (90%) <0.001 
I am confident in my ability to reduce the risk of stroke in 
my patients with sickle cell disease. 68 (49%) 6 (16%) 12 (41%) 50 (69%) <0.001 
I will not recommend chronic exchange transfusion 
regardless of Transcranial Doppler ultrasonography 
results. 
5 (4%) 2 (5%) 2 (7%) 1 (1%) 0.34 
Chronic exchange transfusion is effective at reducing 
stroke risk among children with sickle cell disease. 108 (78%) 18 (46%) 24 (83%) 66 (93%) <0.001 
Hydroxyurea is effective at reducing stroke risk among 




I am comfortable discussing the risks and benefits of 
chronic exchange transfusion with my patients and their 
families. 
89 (64%) 13 (33%) 10 (34%) 66 (93%) <0.001 
*Up to 4 physician responses missing (varies by statement) 





Table 4.3. The Proportion of Knowledge Questions Answered Correctly based on National Heart Lung and 






n = 31 
Pediatric  
Neurologist 
n = 26 
Pediatric  
Hematologist 
n = 70 
p-
value* 
Age to Begin TCD Screening 35% 16% 12% 53% <0.001 
Age to End TCD Screening 20% 3% 8% 33% <0.002 
Sickle Cell Subtypes to Screen 31% 13% 0% 50% <0.003 
Actions to take with Normal TCD Result 31% 10% 15% 46% <0.004 
Actions to take with Conditional TCD Result 22% 10% 12% 33% <0.005 
Actions to take with Abnormal TCD Result 13% 3% 4% 20% 0.002 
*P-value comparing % correct across physician specialties 




Table 4.4 Agreement with Physician-Perceived Barriers for Receipt of Transcranial Doppler Screening, n = 127 
 
 








n = 31 
Pediatric 
Neurology* 
n = 26 
Pediatric 
Hematology* 
n = 70 
p-value** 
Distance from patients' homes to vascular laboratories 
is a barrier to receipt of Transcranial Doppler 
ultrasonography. 
64 (51%) 19 (63%) 7 (27%) 38 (54%) 0.02 
Authorization from private insurance carriers is a 
barrier to receipt of Transcranial Doppler 
ultrasonography. 
38 (30%) 15 (50%) 10 (38%) 13 (19%) 0.004 
Authorization from Medicaid is a barrier to receipt of 
Transcranial Doppler ultrasonography. 26 (21%) 11 (37%) 7 (27%) 8 (11%) 0.01 
Lack of time/resources to describe risks and benefits 
to my patients and families is a barrier to receipt of 
Transcranial Doppler ultrasonography. 
25 (20%) 16 (53%) 4 (15%) 5 (7%) <0.001 
Parental refusal is a barrier to receipt of Transcranial 
Doppler ultrasonography. 32 (26%) 12 (40%) 3 (12%) 17 (24%) 0.06 
Reimbursement from private insurance carriers is a 
barrier to receipt of Transcranial Doppler 
ultrasonography. 
28 (22%) 15 (50%) 8 (31%) 5 (7%) <0.001 
Reimbursement from Medicaid is a barrier to receipt of 
Transcranial Doppler ultrasonography. 22 (18%) 10 (33%) 8 (31%) 4 (6%) <0.001 
Lack of appropriate staff to interpret results is a barrier 
to receipt of Transcranial Doppler ultrasonography. 26 (21%) 7 (23%) 7 (27%) 12 (17%) 0.53 
Low patient adherence to appointments is a barrier to 
receipt of Transcranial Doppler ultrasonography. 70 (56%) 18 (60%) 6 (24%) 46 (66%) 0.001 
Lack of insurance is a barrier to receipt of Transcranial 
Doppler ultrasonography. 40 (32%) 15 (50%) 8 (31%) 17 (24%) 0.04 
Lack of parental belief that their child is at an 
increased risk for stroke is a barrier to receipt of 
Transcranial Doppler ultrasonography. 
51 (41%) 14 (47%) 10 (38%) 27 (39%) 0.73 
*Up to 3 physician responses missing (varies by statement) 








*adapted from Cabana et al95 
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5.1 Overall Summary of Research and Finding 
 
This dissertation investigated factors that may be influencing the low rates of 
TCD screening among children with SCD in the Michigan Medicaid population on 
multiple levels (individual, neighborhood and provider). Identification of these factors 
could inform the utility of targeted interventions aimed at increasing TCD screening 
rates.  
Chapter 2 investigated overall rates of TCD screening and the frequency and 
predictors of missed opportunities for screening. Using Michigan Medicaid 
administrative data, we showed that TCD screening rates were low, particularly among 
adolescents ages 12 to 16. Low rates coupled with high healthcare utilization led to a 
high frequency of missed opportunities for TCD screening, defined as having an SCD-
related healthcare encounter but no receipt of TCD screening within the same year. 
Increasing age was associated with increased odds for a missed opportunity, while 
more than 4 outpatient visits and previous receipt of TCD screening decreased the odds 
for a missed opportunity compared with children with 0-1 outpatient visits and children 
with no previous receipt of screening. Other types of SCD-related healthcare utilization, 




opportunity. Because neighborhood factors may also play a role in receipt of TCD 
screening beyond the individual-level factors investigated in Chapter 2, we considered 
the association between various measures of neighborhood socio-demographic status 
identified from the American Community Survey and receipt of TCD screening among 
children in Wayne County, Michigan in Chapter 3. No associations were found between 
the socio-demographic characteristics of the neighborhoods and receipt of TCD 
screening, nor was any spatial pattern of TCD screening rates across the 
neighborhoods identified. Chapter 4 focused on factors that may influence physician 
adherence to TCD screening guidelines, such as physician awareness, attitudes and 
knowledge of guidelines, along with physician-perceived barriers to screening. These 
factors were explored in a mailed survey to pediatric hematologists, pediatric 
neurologists and PCPs treating children with SCD. Although the majority of physicians 
believed that children with SCD should receive TCD screening and recommended it to 
their patients, significant differences existed in awareness, attitudes and knowledge of 
TCD screening guidelines among specialties. Knowledge of specific TCD 
recommendations was especially low for all physicians. Distance from home to a 
vascular laboratory and patient adherence to appointments were identified by 
physicians as barriers to screening. The culmination of this work suggests that future 
studies are necessary to identify factors associated with TCD screening among children 
with SCD, allowing the design of interventions to increase screening and avert the 
consequences of stroke in this high-risk population. 
 




Chapters 2 and 3 examined variables on both the individual and neighborhood 
level that may affect TCD screening rates among children with SCD in Michigan 
Medicaid. Receipt of TCD screening was low in each year from 2007 to 2011 (10 to 
31%). TCD screening rates increased by 21% over a 5 year period, and younger 
children were more likely to receive screening than teenagers. SCD-related healthcare 
utilization was high and relatively constant over the study period; on average, children 
had 3 outpatient, 1 inpatient and less than 1 ED visit yearly. Given the low TCD 
screening rates and numerous SCD-related healthcare encounters, the frequency of 
missed opportunities for TCD screening was high each year, ranging from 64% to 89%. 
If all missed opportunities were eliminated, TCD screening rates could more than triple. 
We then explored potential correlates for missed opportunities, which included SCD-
related healthcare utilization, SCD comorbidities and demographics. Increasing age was 
associated with presence of a missed opportunity (OR 1.11, CI 1.06, 1.15). This may be 
due to lack of physician recommendation for older children for reasons such as belief 
that stroke risk declines enough past age 10 as to not require TCD screening,103 or less 
interaction with the healthcare system for adolescents. Children with previous receipt of 
TCD screening were less likely to have a missed opportunity than those without a 
previous screening (OR 0.23, CI 0.15, 0.38), perhaps attributable to repeat 
recommendations from the same physician, parental recognition of the need for 
screening, or clinic-specific policies conducive to receipt of TCD screening. Children 
with 4 to 5 (OR 0.44, CI 0.23, 0.83) or 6 or more (OR 0.25, CI 0.13, 0.49) outpatient 
visits compared to children with 0-1 outpatient visits were also less likely to have a 




opportunities to recommend while interacting with the healthcare system. Presence of a 
missed opportunity was not associated with any other SCD-related healthcare utilization 
(i.e. ED, inpatient, hematologist visits), SCD comorbidities (i.e. hypertension, 
pneumococcal infection, severity of disease) or demographics (i.e. sex, sickle cell 
subtype), indicating that these children are not any less likely to have a missed 
opportunity than children without these types of healthcare encounters. Although these 
were not significant relationships, intervention potential exists to reduce missed 
opportunities through these encounters. 
TCD screening rates were similarly low among children with SCD when 
examined in Wayne County, Michigan (7 to 36%), the home of the majority of children 
with SCD in Michigan. The neighborhoods where children with SCD lived had high 
levels of socioeconomic disadvantage and low census tract-level TCD screening rates, 
but no spatial pattern of TCD screening rates was identified across the county. 
Additionally, no association was found between the socio-demographic neighborhood 
factors of median household income, proportion of residents with less than high school 
education, proportion unemployed, or proportion African American residents and receipt 
of TCD screening. The lack of an association between receipt of TCD screening and 
neighborhood-level factors may be due to low levels of screening across all 
neighborhoods, along with high levels of neighborhood disadvantage and little variation 
in these factors between neighborhoods. 
Similar to ours, numerous studies have indicated that TCD screening rates are 
low and children do not receive 1 TCD screening per year as recommended by the 




children with SCD were screened yearly from 2004-2006.42 Rates in a large healthcare 
plan were even lower, with 11.4 screens per 100 person-years from 1999-2005; 
although rates reached as high as 40 screens per 100 person-years in 2002.41 Other 
CSCCs have reported higher rates after initiation of TCD screening programs within the 
center;43,45,55 however, even after implementation of a screening program in 
Philadelphia, children only averaged 3.3 screenings over an 8 year period, falling short 
of NHLBI guidelines.43 Rates of TCD screening have also been increasing over time in 
both a large managed healthcare plan and in CSCCs, especially when comparing rates 
of screening before and after the STOP trial.41,42,45 Our results reflect a similar pattern, 
but are for a later time period than previous studies, providing more recent information 
on the state of TCD screening.  
Although no other study has investigated missed opportunities for TCD screening 
as an outcome, a few have considered predictors of TCD screening. For example, TCD 
screening at a CSCC has been associated with outpatient visits; however, the 
association was for children with more than 1 outpatient visit in a year and our results 
were not significant until children reached at least 4 outpatient visits in a year.45 Another 
CSCC indicated previous receipt of TCD screening was associated with future receipt of 
screening, and younger children were more likely to receive TCD screening than older 
children, similar to our conclusions with missed opportunities.41-43 Further, existing 
studies have reported null associations between neighborhood-level median household 
income, hypertension, SCD severity, sex, and hematology visits and receipt of TCD 
screening.41,42,45 Our work extended the results of these studies by investigating the 




examined additional neighborhood socio-demographic factors in regard to receipt of 
TCD screening.  
These aims advance our knowledge regarding receipt of TCD screening among 
children with SCD. First, the study population is a more accurate representation of the 
population of children with SCD than previous studies, and hence our estimates of TCD 
screening are less likely to be biased. This is the first study of TCD screening using the 
gold standard of newborn screening records to identify children with SCD. Previous 
studies of TCD screening have relied on inpatient and outpatient SCD-related 
administrative claims41,45 or medical records from a CSCC to identify children with 
SCD.42,43,55 Including only children with SCD-related healthcare encounters or who are 
seen at a CSCC may introduce selection bias, as we found that a considerable 
proportion (12 to 16%) of SCD children had no SCD-related health encounters each 
year. These children may be less likely to receive TCD screening due to underutilization 
of healthcare. Indeed, our results show lower rates of screening compared to recent 
studies in CSCCs, which may be a more accurate representation of the true TCD 
screening rates in the population of children with SCD.42,45 
Secondly, investigation of missed opportunities for TCD screening is a novel 
approach to identifying potential intervention targets to increase TCD screening rates. 
Children with missed opportunities have contact with the healthcare system and taking 
advantage of these encounters may provide an appropriate time to initiate screening. 
Missed opportunities for TCD screening have not been enumerated in the population of 
children with SCD. Other studies have focused on the proportion of children receiving 




be any SCD-related healthcare encounter without a TCD screening. These encounters 
may signify additional opportunities to initiate screening within the healthcare system 
beyond merely hematologist or CSCC visits. Our results suggest that some children 
may be at higher risk than others for a missed opportunity, such as older children, 
children that have not received a screening in the past, and children without numerous 
outpatient visits. Interventions aimed at reducing missed opportunities among these 
children may be the most successful avenue to increase screening rates among 
children interacting with the healthcare system. Providers may also play a role in the 
initiation of TCD screening during these healthcare encounters, but their role in the 
recommendation of TCD screening is poorly understood (see Aim 3, section 5.3). 
To date, no study has investigated neighborhood socio-demographic 
characteristics as predictors of receipt of TCD screening beyond median household 
income. Neighborhood of residence may be a determinant of TCD screening as it could 
impact access to resources and levels of social support and stress.74-77 Neighborhood 
socioeconomic status has been shown to be related to all of these constructs; therefore, 
we investigated neighborhood socioeconomic factors (i.e. proportion unemployed, 
proportion less than high school education, and median household income) in relation to 
receipt of TCD screening. In addition, we considered proportion African American 
residents within a neighborhood to be a potential predictor of receipt of screening, as 
utilization of preventive services has been shown to be related to the racial and ethnic 
composition of the neighborhood.78 Although studies have indicated that neighborhood 
level median household income is not associated with the receipt of TCD screening, 




have led to selection bias.42,45 Further, zip code level median household income was 
used as a proxy for individual-level socioeconomic status in predicting receipt of TCD 
screening. Use of smaller units (i.e., census tracts) as done in our current research may 
be a more accurate reflection of the neighborhood ’s socioeconomic status.79 Although 
we expected to find associations between neighborhood socio-demographic factors and 
receipt of TCD screening, none were found. This may be attributable to the low rates of 
screening and high levels of disadvantage in the Wayne County census tracts. It may 
otherwise indicate that we did not capture the neighborhood constructs that may be 
most relevant to TCD screening (see future directions, section 5.5).  
 
5.3 Aim 3 
 Chapter 4 explored physicians’ awareness, attitudes and knowledge of TCD 
screening guidelines for children with SCD. These internal barriers may affect the 
degree of physician adherence to TCD screening and therefore, influence both TCD 
screening rates and the frequency of missed opportunities among children with SCD. 
Physician-perceived external barriers to TCD screening were also identified.  
 The majority of physicians were familiar with national guidelines regarding TCD 
screening; however, one-third did indicate that they felt unfamiliar with guidelines, 
particularly PCPs. Physicians indicated a wide variety of guidelines would be referenced 
when more information was needed; the majority would reference the American 
Academy of Pediatrics guidelines.39 Attitudes regarding screening differed across 
statements and specialties. Most physicians felt comfortable caring for children with 




guidelines; however, the majority of PCPs did not feel well informed regarding the 
guidelines, unlike pediatric hematologists and neurologists who in general, felt well 
informed. Self-efficacy was also lower among PCPs, with this specialty feeling 
uncomfortable discussing risks and benefits of TCD screening and chronic blood 
transfusions, along with their ability to reduce stroke risk in these children. Although 
pediatric hematologists scored consistently higher than pediatric neurologists and PCPs 
in specific knowledge questions regarding TCD screening based on NHLBI guidelines,25 
the proportion of correct was low across all specialties, with the highest proportion 
correct of any question being 35% (age to begin screening). Additionally, physician-
perceived external barriers to TCD screening included distance from a child’s home to a 
vascular laboratory and patient adherence to appointments, despite the fact that patient 
adherence has been shown to be relatively high in a CSSC and missed opportunities for 
screening are numerous.42 
 This aim contributes to the literature by being the first study to investigate 
physician internal and external barriers that may influence TCD screening across 
physician specialties. While our results confirm findings that hematologists identify 
patient adherence to appointments and distance to a vascular laboratory as external 
barriers to TCD screening, no study has included PCPs and pediatric neurologists.47 
The inclusion of pediatric neurologists is advantageous, as children may be referred to 
this specialty after an abnormal TCD screening result. PCPs may be the primary 
physicians seeing children that do not have regular contact with a hematologist; 
therefore, this contact may be the only opportunity in which TCD could be 




adherence to screening in the survey (i.e. physician awareness, attitudes and 
knowledge of TCD screening guidelines) as the previous study included only physician-
perceived external barriers.47 An understanding of the multiple dimensions that may 
affect physician adherence to guidelines can inform the development of more 
appropriate interventions to increase physician recommendation of screening, as 
barriers to physician adherence are likely to be multifaceted.95 In light of our results, 
specialty-specific educational interventions may reduce barriers to physician 
recommendation of TCD screening through increasing self-efficacy, outcome 
expectancy and knowledge of specific TCD screening guidelines. Substantial room for 
improvement exists across all specialties, indicating that physician barriers may be one 
aspect affecting the low TCD screening rates among children with SCD. 
 
5.4 Strengths and Limitations 
 Overall, this dissertation investigated previously unexplored dimensions that may 
be contributing to low rates of TCD screening: missed opportunities, individual and 
neighborhood-level factors, and potential barriers to physician adherence to TCD 
screening guidelines. These multiple levels of influence represent a novel and more 
comprehensive approach to investigating factors that could potentially impact receipt of 
TCD screening among children with SCD than previous work.  
Identification of children with SCD using Newborn Screening records in Aims 1 
and 2 is a novel approach as we did not have to rely on children with SCD-related 
health encounters to identify our study population. Cases of SCD included in our study 




Cell Disease Association of America (SCDAA) Michigan Chapter, and we can assume 
no false positives exist in the identified population of children with SCD used in Aims 1 
and 2.59,104 For both of these analyses, the requirement of continuous enrollment with 
no other forms of health insurance for the study period is also advantageous, as it 
allows for full capture of all healthcare claims for the child. Theoretically, this would 
prevent misclassification of the outcome as we did not miss claims filed with another 
insurance company. In addition, lack of health insurance should not prevent receipt of 
care in this population. The longitudinal nature of the data adds strength, as we 
accounted for the temporal relationship between potential correlates and the presence 
of a missed opportunity. Multiple years of data also allowed several observations per 
child, resulting in an increased sample size and more power to detect associations 
compared to using children as the unit of analysis. 
 Aim 3 is unique as it is the first study to include the subspecialties of pediatric 
neurology and PCPs in a physician survey regarding TCD, along with investigation of 
physician awareness, attitudes and knowledge of guidelines. The framework informing 
the development of the survey was based off results from previous studies investigating 
physician adherence to guidelines.95,105 The survey considered a variety of barriers that 
may be influencing adherence, recognizing that physician recommendation for 
screening has multiple determinants. This framework and survey may be useful in other 
disciplines to determine which approach may be most successful to increase adherence 
to guidelines among physicians. Also, limiting responses to physicians currently treating 




opposed to the population of physicians in general, many of which have no contact with 
children with SCD.  
 There are limitations to each aim of this dissertation. Both aims 1 and 2 had 
similar concerns based off the use of administrative data to identify receipt of TCD 
screening. TCD screening could be miscoded in Medicaid or healthcare providers may 
not have submitted a claim for TCD screening to Medicaid given the low level of 
reimbursement. Both of these circumstances would have led to an under capture of 
receipt of TCD screening, and led to our results showing lower screening rates than the 
true rate in the population of children with SCD. Along similar lines for Aim 1, 
administrative claims data were used for identification of SCD-related healthcare and 
also for potential correlates of missed opportunities. If these claims were reported 
incorrectly, selection bias through improper exclusion from the study population with no 
SCD-related healthcare encounter or information bias regarding classification of the 
correlates could have occurred. Although use of newborn screening to identify cases of 
SCD is a major strength of aims 1 and 2, newborn screening may not have captured all 
cases of SCD, as children may have moved into Michigan and not been captured in 
Michigan Newborn Screening records. In aim 1, there may be other individual-level 
factors influencing TCD screening that were not included, such as pain crises, history of 
stroke within the family, and maternal education.41,45 There also may have been 
additional neighborhood level factors influencing the receipt of TCD screening, such as 
lack of public transportation services, availability of medical services or neighborhood 
safety and disorder. Our results from aims 1 and 2 may not be generalizable to the rest 




Michigan Medicaid. The presence of the SCDAA is strong in Michigan, and may affect 
healthcare such as receipt of TCD screening or care at a CSCC. Further, these aims 
may have been underpowered to find associations with the individual- and 
neighborhood-level predictors. The study design did not allow inclusion of a specific 
number of children (i.e. no formal sample size was determined); instead, every eligible 
child was included that could be identified from 2007-2011. Selection bias may be 
present, as children with SCD have higher mortality than children without SCD; 
however, mortality has declined in the past decades with approximately 94% of children 
with HbSS surviving until the age of 18 years.106 
 Additional limitations exist specifically for aims 1 and 2. The definition of missed 
opportunities in Aim 1 cast a wide net, including all SCD-related healthcare encounters 
with no TCD screening as a missed opportunity. This may overstate true missed 
opportunities; for example, children in the ED may not be an appropriate target for 
reduction of missed opportunities, particularly if the primary reason for the visit was not 
SCD. Although the presence of a missed opportunity was identified, there are no 
indications in administrative claims behind the reason for the missed opportunity. It is 
unknown what course of events led to the lack of TCD screening, as it could be lack of 
physician recommendation, physician recommendation but no appointment scheduled, 
parental refusal, or any host of other situations. Limitations of aim 2 include use of 
census tracts to define neighborhoods as this may not be the most appropriate 
boundaries to reflect the true neighborhood the child/family interacts with and use of the 
urban area of Wayne County only. Although the majority of children with SCD in 




with SCD in rural areas.107 Area-level factors influencing TCD screening may differ 
substantially between rural and urban areas; however, the population of children with 
SCD in Michigan is not an appropriate population to use in evaluation of these 
differences. A further limitation to Aim 2 is the use of the child’s address on January 1 of 
each year to determine residence. Children with SCD have high mobility which may 
have resulted in inappropriate inclusion or exclusion in the study population based on 
their address or assignment to the incorrect neighborhood within Wayne County.  
 For Aim 3, the sample size of physicians was limited due to cost restraints, and 
the response rate of 44% was low. This response rate however is in line with other 
physician surveys and is higher than the response rate of 20% for the survey of US 
hematologists in regard to TCD screening.47,100-102 The low response rate may be a 
problem if the physicians that responded had different awareness, attitudes or 
knowledge of guidelines as compared to physicians that did not answer the survey. 
Additionally, the survey was based on self-report, which may introduce bias in the 
results. The use of PCPs in Michigan only was necessary since they were identified 
using Michigan Medicaid claims data; however, the PCP responses may not be 
generalizable outside of Michigan, or even to the population of PCPs in Michigan if 
response bias is present. A further limitation to note with Aim 3 is that although factors 
that may influence adherence to guidelines were identified, no information regarding the 
actual adherence to guidelines among physicians was available. Therefore, more 






5.5 Future Directions 
Future studies could expand upon the results in this dissertation in two ways: 1) 
additional work addressing methodological considerations, and 2) continued focus on 
the multiple dimensions of influence on TCD screening, including neighborhoods, 
physicians, caregivers and clinics. Additional implications of potential harmonization of 
guidelines and the Affordable Care Act should also be considered.  
Methodological Considerations 
Additional methodological work could be conducted to 1) investigate the 
accuracy of TCD screening as identified through administrative claims and 2) identify 
methods to classify children with SCD when newborn screening information is not 
available. The accuracy of administrative claims in identification of TCD screening 
would require abstraction of medical records for a sample of children with SCD with 
available claims data. If a proportion of screens are not being detected by administrative 
claims data, rates may be higher than reported and would suggest different methods 
are needed to study TCD screening. All states may not have the capacity to perform the 
linkages necessary between Newborn Screening and Medicaid as done in the current 
research; however, alternative strategies are being developed to accurately identify 
children with SCD. These methods use Michigan Medicaid administrative claims data 
for SCD and compare combinations of these claims to the recognized gold standard of 
newborn screening results to determine their sensitivity and specificity in identifying 
children with SCD. Similar methods have been developed for use in quality assessment 
studies of other pediatric conditions, such as asthma and diabetes.108-112 This method 




population in states that are able to perform linkages; for example, children born in 
another state but residing in Michigan. As our study also focused exclusively on children 
enrolled in Michigan Medicaid, other sources of information could increase the number 
of subjects besides those listed above. For example, children with SCD enrolled in 
private insurance could be identified using administrative claims. This could potentially 
increase our sample size by 30-45%. Including these children may be a more accurate 
reflection of TCD screening rates in the total population of children with SCD as 
opposed to the rates among children enrolled in Medicaid. After these issues have been 
addressed, additional study is needed to understand the true rates of TCD screening in 
a broader population of children with SCD than has been previously explored.42,43,45,55  
With a more firm methodological grounding of the accuracy of identification of 
TCD screening rates in a broader population, missed opportunities across other states 
and in other populations could be considered. As each child with SCD interacts with the 
healthcare system, reduction of missed opportunities provides a unique circumstance to 
increase TCD screening rates. An understanding of the frequency missed opportunities 
and their predictors would help identify children at high-risk for a missed opportunity. 
This approach has been successful in interventions aimed at increasing immunization 
rates among children.53,54 Missed opportunities could occur through multiple pathways, 
such as lack of physician recommendation, parental refusal to receive screening, or lack 
of patient adherence to screening appointments.41,42,46,47 These situations require 
different intervention approaches to reduce missed opportunities; therefore, elucidation 
of these situations through the use of medical records and interviews with caregivers 




opportunities can lead to the development of targeted interventions to reduce their 
likelihood. Although children that do not have missed opportunity but also do not receive 
TCD screening are also important targets for increasing TCD screening rates, a 
different methodological approach is necessary to study this population. Also, an 
intervention approach that does not rely on healthcare utilization to initiate screening 
would be necessary for these children. 
Multiple dimensions of Influence on TCD Screening 
Neighborhood Factors 
In recent years, epidemiology has recognized the importance of factors impacting 
health on multiple levels as opposed to merely individual-based explanations.113 
Understanding the social and physical environment in which a person belongs has 
become an area of focus, with neighborhoods being particularly relevant in many 
contexts.113-116 Although we did not identify any neighborhood-level factors associated 
with the receipt of TCD screening or any spatial pattern in TCD screening rates across 
neighborhoods, this may be attributable to the low rates of screening and high levels of 
disadvantage across the Wayne County census tracts. Investigation of socio-
demographic characteristics across neighborhoods showing more variation in 
neighborhood-level TCD screening rates and characteristics may identify potential 
factors associated with screening rates. Additional unmeasured neighborhood factors 
may be influencing rates and could be considered in future studies, such as 
neighborhood safety and disorder, public transportation, and accessibility of medical 
resources. Lack of neighborhood safety and neighborhood disorder have been 




Furthermore, lack of public transportation in a neighborhood may affect TCD screening 
through limiting the accessibility of a CSCC. Rates of TCD screening are higher in 
CSCC with TCD screening programs than in children enrolled in healthcare plans or in 
our study population, indicating children with the ability to utilize a CSCC may be more 
likely to receive TCD screening.42,45,55 These factors have been assessed in other 
studies outside of SCD using standardized scales in interviews, along with non-
interview methods such as videotaped assessments of the neighborhood and use of 
Google Maps to assess neighborhood features.118-120 Assessment of the neighborhoods 
using these methods, along with utilization of administrative claims to identify receipt of 
TCD screening, could begin to explore the relationships between neighborhoods and 
receipt of TCD screening using more refined measures. If neighborhood factors 
associated with TCD screening could be identified, it may be possible to develop more 
cost and resource effective interventions targeting specific neighborhoods to raise TCD 
screening rates, as opposed to a more general intervention to raise TCD screening 
rates across all children with SCD. 
Physician Factors 
Aim 3 identified factors that may influence physician adherence to receipt of TCD 
screening, along with potential barriers to receipt of screening; however, the impact of 
these factors in relation to actual adherence to screening is unknown. One study 
investigated physician adherence to clinic-specific TCD recommendation guidelines; 
however, this was only among hematologists at a CSCC.42 Medical records could be 
used to identify physician recommendation of TCD screening. Then, physician 




recommendation practices to identify which barriers are related to lack of adherence. It 
is important to identify which barriers exist for recommendation of TCD screening 
guidelines so interventions to increase physician adherence to TCD screening 
guidelines can be correctly targeted.95,105 Targeting specific physician-level factors 
influencing screening recommendations by physicians would be a cost and resource-
effective method to impact screening rates.  
Caregiver Factors 
Caregivers may play an important role in the process of receipt of TCD 
screening, and further studies are necessary to clarify the perceptions of the caregiver 
regarding TCD screening. Although one study has investigated caregiver perceptions of 
TCD screening, the sample size was small and the population from one clinic.46 Studies 
should be conducted which include a larger number of caregivers identified through 
many different resources, and should investigate factors such as self-efficacy, 
awareness, outcome expectancy and attitudes toward TCD screening to identify the role 
of the caregiver in the receipt of TCD screening to inform appropriate educational 
interventions for caregivers. 
Clinic Factors 
Identification of additional intervention targets may involve investigation of the 
clinical roadmap of the process in which a child receives TCD screening within clinics. 
This process is not well understood and varies substantially across institutions.42,45,55 
For example, rates of TCD screening have risen substantially when a dedicated nurse is 
in charge of the TCD screening program.55 Also, time between recommendation of TCD 




roadmap. Children with the opportunity to receive screening at the same time as the 
recommendation may be more likely to be screened than children with a separate future 
appointment for TCD screening only.55 Previous studies have shown success at 
increasing TCD screening rates through clinic-based methods such as a dedicated 
individual to follow up on TCD screening, offering TCD screening on-site, and sending 
reminders.42,55 Identification of clinic barriers to TCD screening may allow for a 
restructuring of the hospital or clinic level policy to reflect the most likely process for 
children to receive screening when recommended. 
Harmonization of Guidelines 
 TCD screening guidelines differ substantially across multiple national 
organizations. As we showed that physicians reference many different guidelines for 
information regarding TCD screening, harmonization of these guidelines could 
potentially increase TCD screening rates. Development of a national advisory 
committee would be appropriate to spearhead this effort. Precedent for such a strategy 
has been set by the Advisory Committee on Immunization Practices (ACIP). In 1995, 
the ACIP began releasing yearly harmonized guidelines for childhood immunization 
schedules. Prior to the yearly release, the ACIP published vaccine recommendations 
periodically. A study comparing rates of morbidity and mortality from before and after 
implementation of national recommendations for vaccine preventable diseases (VPD) 
showed 80% reduction of cases and deaths of most diseases targeted since 1980.121 
Given the substantial success of the implementation of national guidelines by an 




advantageous in increasing not only TCD screening, but the quality and consistency of 
care for children with SCD.  
Policy Implications 
 Implementation of the Affordable Care Act (ACA) may provide additional 
opportunities to increase TCD screening through additional funding for community 
health centers and PCPs in medically underserved areas. In 2012, community health 
centers treated 21 million people, the majority of which (62%) were minorities. 
Additionally, 32% of patients were children.122 These centers are generally located in 
underserved and low-income communities, such as the city of Detroit. The ACA 
provides $11 billion over a 5 year period for the expansion of these health centers 
across the US.122 Although all children in this study were covered by health insurance, 
the expansion of health centers could increase TCD screening through reduction of 
missed opportunities by increasing interactions with the healthcare system. Additionally, 
expansion of community health centers may increase the likelihood of the child having a 
medical home due to their emphasis on coordinated and comprehensive care.123 
Children greatly benefit from having a medical home, as it is associated with fewer 
unmet health needs and less delayed care, along with increased receipt of preventive 
care, particularly among children with special health care needs.124-126 Community 
health centers also may reduce other barriers to access to care by providing expanded 
hours, increased convenience of location, and decreased language barriers. 
Furthermore, the ACA aims to increase PCPs working in underserved areas similar to 
Detroit.127 Increased availability of PCPs may increase the likelihood of having a 




have low knowledge, self-efficacy and outcome expectancy regarding TCD screening. 
As PCPs may have consistent contact with children with SCD, particularly in these 
areas, educational interventions regarding the importance of TCD screening, and the 
specific guidelines regarding TCD screening, may be integral to increase TCD 
screening rates among this minority, low-income population. 
An additional way in which policy could affect TCD screening is through 
meaningful use criteria. Meaningful use criteria were developed by the Centers for 
Medicare and Medicaid (CMS) Incentives program. It is the set of standards used to 
measure use of electronic health records (EHR) to allow incentive based payments to 
physicians. Measures of meaningful use include quality measures to improve outcomes, 
processes and systems. Increased use of EHR in concordance with the meaningful use 
criteria may be able to systematically increase TCD screening rates through accurate 
reporting of previous receipt, built-in reminders for upcoming appointments, and 
improvements in the efficiency of the clinical roadmap in which the child receives a TCD 
screening.  
5.6 Conclusion 
 This dissertation addresses factors that may influence TCD screening rates 
among children with SCD. The results indicate that TCD screening rates remain low and 
there is substantial room for improvement through reduction of both missed 
opportunities and barriers to physician adherence to TCD screening guidelines. Further 
investigation of neighborhood-level factors may also identify additional targets for 
improvement. The results of this research, along with additional robust and expanded 




caregiver, and hospital/clinic level that address the receipt of TCD screening. Ultimately, 
these interventions may increase TCD screening among children with SCD and reduce 
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